William Sandborn

Title(s)Recall Hcomp, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Fellowship1993Mayo Clinic
    Intern/Residency1990Loma Linda Univ Medical Center
    MD1987Loma Linda University
    BA1983Southern College

    Collapse Overview 

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis. Expert Rev Clin Pharmacol. 2024 Mar 05; 1-10. D'Haens G, Rosario M, Polhamus D, Dirks NL, Chen C, Kisfalvi K, Agboton C, Vermeire S, Feagan BG, Sandborn WJ. PMID: 38441048.
      View in: PubMed   Mentions:    Fields:    
    2. Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies. Eur J Gastroenterol Hepatol. 2024 Apr 01; 36(4):404-415. D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Sandborn WJ, Dornic Q, Lindner D, Kisfalvi K, Marins EG, Vermeire S. PMID: 38417060; PMCID: PMC10904001.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterol. 2024 Feb 08; 11(1). Jairath V, Zou G, Wang Z, Adsul S, Colombel JF, D'Haens GR, Freire M, Moran GW, Peyrin-Biroulet L, Sandborn WJ, Sebastian S, Travis S, Vermeire S, Radulescu G, Sigler J, Hanžel J, Ma C, Sedano R, McFarlane SC, Arya N, Beaton M, Bossuyt P, Danese S, Green D, Harlan W, Horynski M, Klopocka M, Petroniene R, Silverberg MS, Wolanski L, Feagan BG. PMID: 38336367; PMCID: PMC10870790.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    4. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis. J Crohns Colitis. 2024 Feb 04. Ghosh S, Feagan BG, Ott E, Gasink C, Godwin B, Marano C, Miao Y, Ma T, Loftus EV, Sandborn WJ, Danese S, Abreu MT, Sands BE. PMID: 38310565.
      View in: PubMed   Mentions:    Fields:    
    5. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study. Am J Gastroenterol. 2024 Jan 26. Afif W, Arasaradnam RP, Abreu MT, Danese S, Sandborn WJ, Miao Y, Zhang H, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Peyrin-Biroulet L, Sands BE, Marano C. PMID: 38095692.
      View in: PubMed   Mentions: 1     Fields:    
    6. Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial. J Crohns Colitis. 2024 Jan 20. Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. PMID: 38245818.
      View in: PubMed   Mentions:    Fields:    
    7. Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis. J Crohns Colitis. 2023 Dec 23. Hassan-Zahraee M, Ye Z, Xi L, Dushin E, Lee J, Romatowski J, Leszczyszyn J, Danese S, Sandborn WJ, Banfield C, Gale JD, Peeva E, Longman RS, Hyde CL, Hung KE. PMID: 38141256.
      View in: PubMed   Mentions:    Fields:    
    8. Pangenome comparison of Bacteroides fragilis genomospecies unveil genetic diversity and ecological insights. bioRxiv. 2023 Dec 21. Oles RE, Terrazas MC, Loomis LR, Hsu CY, Tribelhorn C, Ferre PB, Ea A, Bryant M, Young J, Carrow HC, Sandborn WJ, Dulai P, Sivagnanam M, Pride D, Knight R, Chu H. PMID: 38187556; PMCID: PMC10769428.
      View in: PubMed   Mentions:
    9. Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1. Crohns Colitis 360. 2024 Jan; 6(1):otad076. Sandborn WJ, Sands BE, Uddin S, Qasim Khan RM, Sagar Mukherjee R. PMID: 38213631; PMCID: PMC10782208.
      View in: PubMed   Mentions:
    10. Efficacy and Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2023 Dec 14. Vermeire S, Danese S, Sandborn WJ, Schreiber S, Hanauer S, D'Haens G, Nagy P, Thakur M, Bliss C, Cataldi F, Goetsch M, Gorelick KJ, Reinisch W. PMID: 38096402.
      View in: PubMed   Mentions:    Fields:    
    11. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024 Feb; 9(2):133-146. Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI-1 Study Group. PMID: 38104569.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    12. Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease. J Patient Rep Outcomes. 2023 Nov 14; 7(1):115. Feagan BG, Sandborn WJ, Sands BE, Liu Y, Vetter M, Mathias SD, Huang KG, Johanns J, Germinaro M, Han C. PMID: 37962770; PMCID: PMC10645698.
      View in: PubMed   Mentions: Translation:HumansAnimals
    13. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023 Dec; 165(6):1443-1457. Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A, QUASAR Study Group. PMID: 37659673.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    14. Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies. Crohns Colitis 360. 2023 Jul; 5(3):otad034. Sandborn WJ, Chen J, Kisfalvi K, Loftus EV, D'Haens G, Candela N, Lasch K, Wolf DC, Uddin SM, Danese S. PMID: 37636008; PMCID: PMC10449415.
      View in: PubMed   Mentions:
    15. Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study. Clin Transl Gastroenterol. 2023 07 01; 14(7):e00578. Steere B, Schmitz J, Powell N, Higgs R, Gottlieb K, Liu Y, Jia B, Tuttle JL, Sandborn WJ, Sands BE, D'Haens G, Reinisch W, Krishnan V. PMID: 36881820; PMCID: PMC10371316.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    16. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2023 Jun 29; 388(26):2444-2455. D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE, LUCENT Study Group. PMID: 37379135.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    17. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024 01; 22(1):144-153.e2. Colombel JF, Sands BE, Gasink C, Yeager B, Adedokun OJ, Izanec J, Ma T, Gao LL, Lee SD, Targan SR, Ghosh S, Hanauer SB, Sandborn WJ. PMID: 37391056.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    18. A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Aliment Pharmacol Ther. 2023 08; 58(3):283-296. D'Haens G, Peyrin-Biroulet L, Marks DJB, Lisi E, Liefaard L, Beaton A, Srinivasan N, Bouma G, Prasad N, Cameron R, Kayali Z, Tarzi R, Hanauer S, Sandborn WJ. PMID: 37323059.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    19. Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study. Clin Gastroenterol Hepatol. 2023 10; 21(11):2938-2950.e6. Khanna R, Ma C, Hogan M, Zou G, Bessissow T, Bressler B, Colombel JF, Danese S, Daperno M, East JE, Hookey L, Loftus EV, McDonald JWD, Panaccione R, Peyrin-Biroulet L, Rutter M, Sands BE, Vermeire S, Rémillard J, McFarlane SC, Sandborn WJ, D'Haens GR, Feagan BG, Jairath V. PMID: 37308036.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme. J Crohns Colitis. 2023 Apr 03; 17(3):338-351. Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Modesto I, Guo X, Mundayat R, Su C, Vranic I, Panés J. PMID: 36124702; PMCID: PMC10069618.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    21. A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. Inflamm Bowel Dis. 2023 04 03; 29(4):555-562. Holmer AK, Boland BS, Singh S, Neill J, Le H, Miralles A, Collins AE, Sandborn WJ, Dulai PS. PMID: 35704691; PMCID: PMC10069658.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study. J Crohns Colitis. 2023 Mar 18; 17(2):211-220. Loftus EV, Vermeire S, Feagan BG, Le Brun FO, Oortwijn A, Moerch U, Sandborn WJ, Hibi T. PMID: 36006011; PMCID: PMC10024544.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. A Living Organoid Biobank of Crohn's Disease Patients Reveals Molecular Subtypes for Personalized Therapeutics. bioRxiv. 2023 Mar 13. Tindle C, Katkar GD, Fonseca AG, Taheri S, Lee J, Maity P, Sayed IM, Ibeawuchi SR, Vidales E, Pranadinata RF, Fuller M, Stec DL, Anandachar MS, Perry K, Le HN, Ear J, Boland BS, Sandborn WJ, Sahoo D, Das S, Ghosh P. PMID: 36993763; PMCID: PMC10054961.
      View in: PubMed   Mentions:
    24. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023 04 08; 401(10383):1159-1171. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG. PMID: 36871574.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    25. The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn's Disease but Not Ulcerative Colitis Patients. Pharmaceutics. 2023 Mar 02; 15(3). Park YS, Kang SB, Marchelletta RR, Penrose HM, Ruiter-Visser R, Jung B, Docherty MJ, Boland BS, Sandborn WJ, McCole DF. PMID: 36986672; PMCID: PMC10053841.
      View in: PubMed   Mentions: 1  
    26. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023 04; 8(4):307-320. Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panés J, VEGA Study Group. PMID: 36738762.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    27. A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy. Sci Adv. 2023 01 20; 9(3):eadd1166. Mayer AT, Holman DR, Sood A, Tandon U, Bhate SS, Bodapati S, Barlow GL, Chang J, Black S, Crenshaw EC, Koron AN, Streett SE, Gambhir SS, Sandborn WJ, Boland BS, Hastie T, Tibshirani R, Chang JT, Nolan GP, Schürch CM, Rogalla S. PMID: 36662860; PMCID: PMC9858501.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    28. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. Clin Gastroenterol Hepatol. 2023 09; 21(10):2616-2628.e7. Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, Hassan-Zahraee M, Vincent MS, Reddy PS, Banfield C, Salganik M, Banerjee A, Gale JD, Hung KE. PMID: 36623678.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    29. High Discovery Rate of Duodenal and Gastric Eosinophilia in Patients With Unexplained Moderate-Severe Abdominal Symptoms: A Prospective US Multisite Study. Gastroenterology. 2023 04; 164(4):680-683.e2. Talley NJ, Peterson KA, Genta RM, Chang AT, Dellon ES, Sandborn WJ, 019 Study Team, Lacy BE, Chehade M, Hirano I, Gonsalves N, Lembo A, Schmitt CM, Rothenberg ME, Jain N, Pletneva MA, Turner KO, Youngblood BA. PMID: 36574864.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    30. Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. Therap Adv Gastroenterol. 2022; 15:17562848221136331. Sandborn WJ, Sands BE, Vermeire S, Leung Y, Guo X, Modesto I, Su C, Wang W, Panés J. PMID: 36506749; PMCID: PMC9726836.
      View in: PubMed   Mentions: 3  
    31. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study. Clin Gastroenterol Hepatol. 2023 08; 21(9):2359-2369.e5. Singh S, Kim J, Luo J, Paul P, Rudrapatna V, Park S, Zheng K, Syal G, Ha C, Fleshner P, McGovern D, Sauk JS, Limketkai B, Dulai PS, Boland BS, Eisenstein S, Ramamoorthy S, Melmed G, Mahadevan U, Sandborn WJ, Ohno-Machado L. PMID: 36343846.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    32. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2022 Oct 11. Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, Daperno M, Valentine JF, Laharie D, Baía C, Atreya R, Panaccione R, Rydzewska G, Aguilar H, Vermeire S, BERGAMOT Study Group. PMID: 36240801.
      View in: PubMed   Mentions: 9     Fields:    
    33. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. Am J Gastroenterol. 2023 02 01; 118(2):317-328. Johnson AM, Barsky M, Ahmed W, Zullow S, Galati J, Jairath V, Narula N, Peerani F, Click BH, Coburn ES, Dang TT, Gold S, Agrawal M, Garg R, Aggarwal M, Mohammad D, Halloran B, Kochhar GS, Todorowski H, Ud Din NM, Izanec J, Teeple A, Gasink C, Muser E, Ding Z, Swaminath A, Lakhani K, Hogan D, Datta S, Ungaro RC, Boland BS, Bohm M, Fischer M, Sagi S, Afzali A, Ullman T, Lawlor G, Baumgart DC, Chang S, Hudesman D, Lukin D, Scherl EJ, Colombel JF, Sands BE, Siegel CA, Regueiro M, Sandborn WJ, Bruining D, Kane S, Loftus EV, Dulai PS. PMID: 36191274.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    34. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. Clin Ther. 2022 Oct; 44(10):1336-1355. Adedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B. PMID: 36150926.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    35. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol Hepatol. 2022 11; 7(11):1024-1035. Vermeire S, Sands BE, Tilg H, Tulassay Z, Kempinski R, Danese S, Bunganic I, Nitcheu J, Santo J, Scherrer D, Biguenet S, Ehrlich HJ, Steens JM, Gineste P, Sandborn WJ. PMID: 36075249.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    36. Reply. Gastroenterology. 2022 Sep 05. D'Haens GR, Sandborn WJ. PMID: 36067821.
      View in: PubMed   Mentions:    Fields:    
    37. Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. Inflamm Bowel Dis. 2022 09 01; 28(9):1321-1331. Hanzel J, Jairath V, De Cruz P, Guizzetti L, Shackelton LM, Bossuyt P, Duijvestein M, Dulai PS, Grossmann J, Hirten RP, Khanna R, Panes J, Peyrin-Biroulet L, Regueiro M, Rubin DT, Singh S, Stidham RW, Sandborn WJ, Feagan BG, D'Haens GR, Ma C. PMID: 34791254.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    38. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2022 09 01; 28(9):1338-1347. Sandborn WJ, Armuzzi A, Liguori G, Irving PM, Sharara AI, Mundayat R, Lawendy N, Woolcott JC, Danese S. PMID: 34958359; PMCID: PMC9434448.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    39. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. J Crohns Colitis. 2022 Aug 30; 16(8):1222-1234. Abreu MT, Rowbotham DS, Danese S, Sandborn WJ, Miao Y, Zhang H, Tikhonov I, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Arasaradnam RP, Afif W, Peyrin-Biroulet L, Sands BE, Marano C. PMID: 35239968; PMCID: PMC9426670.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    40. Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial. Am J Gastroenterol. 2023 01 01; 118(1):138-147. Danese S, Ferrante M, Feagan BG, Peyrin-Biroulet L, Hibi T, Sandborn WJ, Schreiber S, Ritter T, Loftus EV, Rogler G, Oortwijn A, Yun C, Le Brun FO, Dinoso J, Hsieh J, Vermeire S. PMID: 36113491; PMCID: PMC9810009.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    41. Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022 12; 163(6):1555-1568. Chen B, Zhong J, Li X, Pan F, Ding Y, Zhang Y, Chen H, Liu F, Zhang Z, Zhang L, Drozda R, Oliinyk O, Goh AH, Chen X, Sun X, Rubin DT, Sandborn WJ, Chen M. PMID: 35963369.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    42. Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review. J Crohns Colitis. 2022 Jul 14; 16(6):922-930. Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. PMID: 34850857.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    43. Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 09; 7(9):871-893. Kiran RP, Kochhar GS, Kariv R, Rex DK, Sugita A, Rubin DT, Navaneethan U, Hull TL, Ko HM, Liu X, Kachnic LA, Strong S, Iacucci M, Bemelman W, Fleshner P, Safyan RA, Kotze PG, D'Hoore A, Faiz O, Lo S, Ashburn JH, Spinelli A, Bernstein CN, Kane SV, Cross RK, Schairer J, McCormick JT, Farraye FA, Chang S, Scherl EJ, Schwartz DA, Bruining DH, Philpott J, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sandborn WJ, Silverberg MS, Pardi DS, Church JM, Shen B. PMID: 35798022.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964. CORE-IBD Collaborators, Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, Fleshner PR, Gearry RB, Hanauer SB, Hart A, Kotze PG, Kucharzik T, Lakatos PL, Leong RW, Magro F, Panés J, Peyrin-Biroulet L, Ran Z, Regueiro M, Singh S, Spinelli A, Steinhart AH, Travis SP, van der Woude CJ, Yacyshyn B, Yamamoto T, Allez M, Bemelman WA, Lightner AL, Louis E, Rubin DT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC, Guizzetti L, Smith MI, Vande Casteele N, Feagan BG, Jairath V. PMID: 35788348.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    45. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflamm Bowel Dis. 2022 07 01; 28(7):1034-1044. D'Haens GR, Reinisch W, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Schreiber S, Il Park D, Hébuterne X, Nagy P, Cataldi F, Martin SW, Nayak S, Banerjee A, Gorelick KJ, Sandborn WJ. PMID: 34427633; PMCID: PMC9247846.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    46. Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials. J Crohns Colitis. 2022 Jun 24; 16(5):717-736. Almradi A, Sedano R, Hogan M, Zou GY, MacDonald JK, Parker CE, Hanzel J, Crowley E, Singh S, D'Haens G, Sandborn WJ, Feagan BG, Ma C, Jairath V. PMID: 34758084.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    47. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211. Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ, SEAVUE Study Group. PMID: 35691323.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    48. Simplified Machine Learning Models Can Accurately Identify High-Need High-Cost Patients With Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2022 07 01; 13(7):e00507. Nguyen NH, Patel S, Gabunilas J, Qian AS, Cecil A, Jairath V, Sandborn WJ, Ohno-Machado L, Chen PL, Singh S. PMID: 35905414; PMCID: PMC10476830.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    49. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. Am J Gastroenterol. 2022 10 01; 117(10):1639-1647. Gu P, Luo J, Kim J, Paul P, Limketkai B, Sauk JS, Park S, Parekh N, Zheng K, Rudrapatna V, Syal G, Ha C, McGovern DP, Melmed GY, Fleshner P, Eisenstein S, Ramamoorthy S, Dulai PS, Boland BS, Grunvald E, Mahadevan U, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 35973139.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    50. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 05 28; 399(10340):2015-2030. D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. PMID: 35644154.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    51. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 05 28; 399(10340):2031-2046. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. PMID: 35644155.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    52. Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. Clin Gastroenterol Hepatol. 2023 01; 21(1):173-181.e5. Nguyen NH, Luo J, Paul P, Kim J, Syal G, Ha C, Rudrapatna V, Park S, Parekh N, Zheng K, Sauk JS, Limketkai B, Fleshner P, Eisenstein S, Ramamoorthy S, Melmed G, Dulai PS, Boland BS, Mahadevan U, Sandborn WJ, Ohno-Machado L, McGovern D, Singh S. PMID: 35644340; PMCID: PMC9701245.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022 06 04; 399(10341):2113-2128. Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. PMID: 35644166.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCTClinical Trials
    54. Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease. J Crohns Colitis. 2022 May 10; 16(4):616-624. Narula N, Wong ECL, Colombel JF, Sandborn WJ, Ferrante M, Marshall JK, Reinisch W, Dulai PS. PMID: 34664635; PMCID: PMC9274823.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    55. A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2022 05 04; 28(5):788-800. Tse CS, Singh S, Sandborn WJ. PMID: 34244749.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Clin Pharmacol Ther. 2022 07; 112(1):90-100. Mukherjee A, Tsuchiwata S, Nicholas T, Cook JA, Modesto I, Su C, D'Haens GR, Sandborn WJ. PMID: 35380740; PMCID: PMC9322343.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    57. Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. Aliment Pharmacol Ther. 2022 08; 56(3):463-476. Vande Casteele N, Sandborn WJ, Feagan BG, Vermeire S, Dulai PS, Yarur A, Roblin X, Ben-Horin S, Dotan I, Osterman MT, Rosario M, Osborn TM, Panes J, Lindner D, Agboton C. PMID: 35474325.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    58. Disease Activity Indices for Pouchitis: A Systematic Review. Inflamm Bowel Dis. 2022 03 30; 28(4):622-638. Sedano R, Nguyen TM, Almradi A, Rieder F, Parker CE, Shackelton LM, D'Haens G, Sandborn WJ, Feagan BG, Ma C, Jairath V. PMID: 34180986; PMCID: PMC8972820.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    59. Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis. 2022 Mar 14; 16(3):398-413. Nguyen NH, Picetti D, Dulai PS, Jairath V, Sandborn WJ, Ohno-Machado L, Chen PL, Singh S. PMID: 34492100; PMCID: PMC8919806.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    60. The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2022 Mar 14; 16(3):490-499. Ble A, Renzulli C, Cenci F, Grimaldi M, Barone M, Sedano R, Chang J, Nguyen TM, Hogan M, Zou G, MacDonald JK, Ma C, Sandborn WJ, Feagan BG, Merlo Pich E, Jairath V. PMID: 34508572; PMCID: PMC8919832.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    61. Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease. J Crohns Colitis. 2022 Mar 14; 16(3):444-451. Sandborn WJ, Lewis JD, Panes J, Loftus EV, D'Haens G, Yu Z, Huang B, Lacerda AP, Pangan AL, Feagan BG. PMID: 34546360; PMCID: PMC8919823.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    62. Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease. Commun Biol. 2022 03 14; 5(1):231. Katkar GD, Sayed IM, Anandachar MS, Castillo V, Vidales E, Toobian D, Usmani F, Sawires JR, Leriche G, Yang J, Sandborn WJ, Das S, Sahoo D, Ghosh P. PMID: 35288651; PMCID: PMC8921270.
      View in: PubMed   Mentions: 4  Translation:HumansAnimalsCells
    63. Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. Inflamm Bowel Dis. 2022 03 02; 28(3):364-372. Singh S, Qian AS, Nguyen NH, Ho SKM, Luo J, Jairath V, Sandborn WJ, Ma C. PMID: 33988697; PMCID: PMC8889287.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    64. Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data. Clin Gastroenterol Hepatol. 2023 05; 21(5):1348-1350. Kayal M, Ungaro RC, Bader G, Colombel JF, Sandborn WJ, Stalgis C. PMID: 35245701.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    65. Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply. Aliment Pharmacol Ther. 2022 03; 55(6):735-736. Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Meadows KT, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. PMID: 35245951.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Design of Clinical Trials for Mild to Moderate Crohn's Disease. Gastroenterology. 2022 06; 162(7):1800-1814.e1. Hanzel J, Ma C, Jairath V, IBD Trial Design Group. PMID: 35240140.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    67. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. Gastroenterology. 2022 06; 162(7):1891-1910. Panés J, Colombel JF, D'Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Hibi T, Watanabe M, Lefebvre J, Finney-Hayward T, Sanchez Gonzalez Y, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ. PMID: 35227777.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    68. Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2022 Feb 23; 16(2):224-243. Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Vande Casteele N, Hanzel J, Crowley E, Battat R, Dulai PS, Singh S, D'Haens G, Sandborn W, Feagan BG, Ma C, Jairath V. PMID: 34309658.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    69. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clin Gastroenterol Hepatol. 2022 11; 20(11):2619-2627.e1. Caron B, Abreu MT, Siegel CA, Panaccione R, Sands BE, Dignass A, Turner D, Dotan I, Hart AL, Ahuja V, Allez M, Ananthakrishnan AN, Ghosh S, Griffiths AM, Halfvarson J, Kaser A, Kotze PG, Koutroubakis IE, Lakatos PL, Levine A, Lewis JD, Magro F, Mantzaris GJ, O'Morain C, Ran Z, Reinisch W, Rogler G, Sachar DB, Siegmund B, Silverberg MS, Sood A, Spinelli A, Steinwurz F, Tysk C, Yamamoto-Furusho JK, Schreiber S, Rubin DT, Sandborn WJ, Danese S, Peyrin-Biroulet L. PMID: 35189386.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    70. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022 05; 162(6):1650-1664.e8. Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG, GALAXI-1 Investigators. PMID: 35134323.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    71. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022 06; 162(7):1876-1890. D'Haens GR, Sandborn WJ, Loftus EV, Hanauer SB, Schreiber S, Peyrin-Biroulet L, Panaccione R, Panés J, Baert F, Colombel JF, Ferrante M, Louis E, Armuzzi A, Zhou Q, Goteti VS, Mostafa NM, Doan TT, Petersson J, Finney-Hayward T, Song AP, Robinson AM, Danese S. PMID: 35122766.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    72. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022 02; 7(2):171-185. Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L, International Consortium for Therapeutic Drug Monitoring. PMID: 35026171; PMCID: PMC10187071.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    73. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis. 2022 Jan 28; 16(1):27-38. Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ. PMID: 34402887; PMCID: PMC8797168.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    74. Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nat Microbiol. 2022 02; 7(2):262-276. Mills RH, Dulai PS, Vázquez-Baeza Y, Sauceda C, Daniel N, Gerner RR, Batachari LE, Malfavon M, Zhu Q, Weldon K, Humphrey G, Carrillo-Terrazas M, Goldasich LD, Bryant M, Raffatellu M, Quinn RA, Gewirtz AT, Chassaing B, Chu H, Sandborn WJ, Dorrestein PC, Knight R, Gonzalez DJ. PMID: 35087228; PMCID: PMC8852248.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    75. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022 03; 7(3):254-261. Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, Korelitz B, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, Ng SC, O'Morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB, Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, Haemel AK, Dignass A, Sands BE, Danese S, Peyrin-Biroulet L. PMID: 35051383.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    76. Ozanimod for Ulcerative Colitis. Reply. N Engl J Med. 2022 01 13; 386(2):194-195. Sandborn WJ, Danese S. PMID: 35020995.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    77. Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. Aliment Pharmacol Ther. 2022 02; 55(4):401-411. Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Taylor Meadows K, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. PMID: 35014040; PMCID: PMC9305136.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    78. Design of Clinical Trials for Mild to Moderate Ulcerative Colitis. Gastroenterology. 2022 04; 162(4):1005-1018. Sedano R, Jairath V, Ma C, IBD Trial Design Group. PMID: 34998800.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    79. Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review. Am J Gastroenterol. 2022 01 01; 117(1):78-97. Nguyen NH, Martinez I, Atreja A, Sitapati AM, Sandborn WJ, Ohno-Machado L, Singh S. PMID: 34751673; PMCID: PMC8987011.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    80. A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. BioDrugs. 2022 Jan; 36(1):85-93. Lefevre PLC, Dulai PS, Wang Z, Guizzetti L, Feagan BG, Pop A, Yassine M, Shackelton LM, Jairath V, Sandborn WJ, Vande Casteele N. PMID: 34951696.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    81. Class Ib MHC-Mediated Immune Interactions Play a Critical Role in Maintaining Mucosal Homeostasis in the Mammalian Large Intestine. Immunohorizons. 2021 12 15; 5(12):953-971. Dasgupta S, Maricic I, Tang J, Wandro S, Weldon K, Carpenter CS, Eckmann L, Rivera-Nieves J, Sandborn W, Knight R, Dorrestein P, Swafford AD, Kumar V. PMID: 34911745; PMCID: PMC10026853.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    82. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021; 14:17562848211059954. Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. PMID: 34917173; PMCID: PMC8669878.
      View in: PubMed   Mentions: 8  
    83. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022 02; 55(4):464-478. Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. PMID: 34854095; PMCID: PMC9300081.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    84. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy. Dig Dis Sci. 2022 07; 67(7):3115-3123. Picetti D, Kim J, Zhu W, Sandborn WJ, Jairath V, Singh S. PMID: 34797442; PMCID: PMC9117569.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioDrugs. 2021 Nov; 35(6):715-733. Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D'Haens G, Vande Casteele N. PMID: 34797516.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    86. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2022 02; 7(2):128-140. Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ, HICKORY Study Group. PMID: 34798039.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    87. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95. Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP, Fleshner P, McCormick JT, D'Hoore A, Shah SA, Farraye FA, Kariv R, Liu X, Rosh J, Chang S, Scherl E, Schwartz DA, Kotze PG, Bruining DH, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, Picoraro JA, Vermeire S, Sandborn WJ, Silverberg MS, Pardi DS. PMID: 34774224.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansPHPublic Health
    88. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology. 2022 02; 162(2):495-508. Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D'Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ. PMID: 34748774.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    89. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021 12; 6(12):1002-1014. Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. PMID: 34688373; PMCID: PMC8933137.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    90. Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 10 18; 27(10):1626-1633. Singh S, Heien HC, Sangaralingham L, Shah ND, Lai JC, Sandborn WJ, Moore AA. PMID: 33325507; PMCID: PMC8522787.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    91. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Aliment Pharmacol Ther. 2021 12; 54(11-12):1442-1453. Feagan BG, Khanna R, Sandborn WJ, Vermeire S, Reinisch W, Su C, Salese L, Fan H, Paulissen J, Woodworth DA, Niezychowski W, Sands BE. PMID: 34614208; PMCID: PMC9291991.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    92. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 09 30; 385(14):1280-1291. Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S, True North Study Group. PMID: 34587385.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCTClinical Trials
    93. Correction to: Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. Dig Dis Sci. 2021 Sep; 66(9):3216. Barsky M, Meserve J, Le H, Collins A, Singh S, Boland B, Sandborn WJ, Dulai PS. PMID: 33555517.
      View in: PubMed   Mentions:    Fields:    
    94. PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. Gastroenterology. 2021 12; 161(6):1853-1864.e10. Sandborn WJ, Mattheakis LC, Modi NB, Pugatch D, Bressler B, Lee S, Bhandari R, Kanwar B, Shames R, D'Haens G, Schreiber S, Danese S, Feagan B, Pai RK, Liu DY, Gupta S. PMID: 34474038.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    95. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021 10; 6(10):826-849. Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J, Farraye FA, Kiran RP, Fleshner P, Rosh J, Shah SA, Chang S, Scherl E, Pardi DS, Schwartz DA, Kotze PG, Bruining DH, Kane SV, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, McCormick JT, Picoraro JA, Silverberg MS, Bernstein CN, Sandborn WJ, Vermeire S. PMID: 34416186.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    96. Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn's Disease in Population-Based Cohort Studies. Dig Dis Sci. 2022 06; 67(6):2451-2461. Tsai L, Nguyen NH, Ma C, Prokop LJ, Sandborn WJ, Singh S. PMID: 34379220; PMCID: PMC8831664.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    97. A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. Am J Gastroenterol. 2021 08 01; 116(8):1709-1719. Dulai PS, Jairath V, Narula N, Wong E, Kochhar GS, Colombel JF, Sandborn WJ. PMID: 34587127; PMCID: PMC8481677.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    98. Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. Inflamm Bowel Dis. 2021 07 27; 27(8):1277-1284. Yoon H, Jangi S, Dulai PS, Boland BS, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 33236763; PMCID: PMC8314112.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    99. Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease. Inflamm Bowel Dis. 2021 07 27; 27(8):1215-1223. Rozich JJ, Luo J, Dulai PS, Collins AE, Pham L, Boland BS, Sandborn WJ, Singh S. PMID: 33252124; PMCID: PMC8314101.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    100. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. Inflamm Bowel Dis. 2021 07 27; 27(8):1346-1355. Vande Casteele N, Feagan BG, Wolf DC, Pop A, Yassine M, Horst SN, Ritter TE, Sandborn WJ. PMID: 33051647; PMCID: PMC8314098.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    101. Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease. Nat Commun. 2021 07 12; 12(1):4246. Sahoo D, Swanson L, Sayed IM, Katkar GD, Ibeawuchi SR, Mittal Y, Pranadinata RF, Tindle C, Fuller M, Stec DL, Chang JT, Sandborn WJ, Das S, Ghosh P. PMID: 34253728; PMCID: PMC8275683.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    102. Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases. Clin Transl Gastroenterol. 2021 07 06; 12(7):e00380. Singh S, Heien HC, Sangaralingham L, Shah ND, Sandborn WJ. PMID: 34228004; PMCID: PMC8260899.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    103. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis. 2021 Jul 05; 15(7):1130-1141. Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, Panés J. PMID: 33290538; PMCID: PMC8256630.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    104. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 05; 15(7):1120-1129. Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G. PMID: 33438008; PMCID: PMC8256627.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    105. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. J Crohns Colitis. 2021 Jun 22; 15(6):950-959. Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ. PMID: 33475734; PMCID: PMC8218705.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    106. Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. J Crohns Colitis. 2021 Jun 22; 15(6):938-949. Reinisch W, Sandborn WJ, Danese S, Hébuterne X, Klopocka M, Tarabar D, Vanásek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hoy M, Goetsch M, Bliss C, Gupta C, Cataldi F, Vermeire S. PMID: 33599720; PMCID: PMC8218706.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    107. National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States. Inflamm Bowel Dis. 2021 06 15; 27(7):1068-1078. Nguyen NH, Khera R, Dulai PS, Boland BS, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 33051681; PMCID: PMC8205631.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    108. Burden and Outcomes of Fragmentation of Care in Hospitalized Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort. Inflamm Bowel Dis. 2021 06 15; 27(7):1026-1034. Nguyen NH, Luo J, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 32944753; PMCID: PMC8205632.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    109. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflamm Bowel Dis. 2021 06 15; 27(7):994-1007. Sandborn WJ, Feagan BG, Danese S, O'Brien CD, Ott E, Marano C, Baker T, Zhou Y, Volger S, Tikhonov I, Gasink C, Sands BE, Ghosh S. PMID: 32964215; PMCID: PMC8205635.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    110. Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2022 06; 67(6):2039-2048. Nguyen NH, Zhang X, Long MD, Sandborn WJ, Kappelman MD, Singh S. PMID: 34110539; PMCID: PMC8986995.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    111. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021 06 19; 397(10292):2372-2384. Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempinski R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. PMID: 34090625.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCTClinical Trials
    112. Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2022 06; 67(6):2510-2516. Singh S, Heien HC, Sangaralingham L, Shah ND, Sandborn WJ. PMID: 34085174; PMCID: PMC8933138.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    113. International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease. Gut. 2022 03; 71(3):479-486. Gordon IO, Bettenworth D, Bokemeyer A, Srivastava A, Rosty C, de Hertogh G, Robert ME, Valasek MA, Mao R, Li J, Harpaz N, Borralho P, Pai RK, Odze R, Feakins R, Parker CE, Guizzetti L, Nguyen T, Shackelton LM, Sandborn WJ, Jairath V, Baker M, Bruining D, Fletcher JG, Feagan BG, Pai RK, Rieder F, Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. PMID: 33952604; PMCID: PMC8903083.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    114. Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2021 06; 6(6):482-497. Shen B, Kochhar GS, Navaneethan U, Cross RK, Farraye FA, Iacucci M, Schwartz DA, Gonzalez-Lama Y, Schairer J, Kiran RP, Kotze PG, Kobayashi T, Bortlik M, Liu X, Levy AN, González Suárez B, Tang SJ, Coelho-Prabhu N, Lukas M, Bruining DH, El-Hachem S, Charles RJ, Chen Y, Sood A, Mao R, Loras C, Dulai PS, Picoraro JA, Chiorean M, Lukas M, Shergill A, Silverberg MS, Sandborn WJ, Bernstein CN. PMID: 33872568.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    115. Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. Inflamm Bowel Dis. 2021 04 15; 27(5):639-646. Dulai PS, Jairath V, Zou G, Stitt LW, Khanna R, Sandborn WJ, Feagan BG, Singh S. PMID: 32592481; PMCID: PMC8243599.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    116. Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity. Inflamm Bowel Dis. 2021 04 15; 27(5):603-616. Fang X, Vázquez-Baeza Y, Elijah E, Vargas F, Ackermann G, Humphrey G, Lau R, Weldon KC, Sanders JG, Panitchpakdi M, Carpenter C, Jarmusch AK, Neill J, Miralles A, Dulai P, Singh S, Tsai M, Swafford AD, Smarr L, Boyle DL, Palsson BO, Chang JT, Dorrestein PC, Sandborn WJ, Knight R, Boland BS. PMID: 33026068; PMCID: PMC8047854.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    117. Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint. J Crohns Colitis. 2021 Apr 06; 15(4):567-574. Jangi S, Holmer AK, Dulai PS, Boland BS, Collins AE, Pham L, Sandborn WJ, Singh S. PMID: 32914194; PMCID: PMC8023862.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    118. Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clin Gastroenterol Hepatol. 2022 07; 20(7):1436-1449. Battat R, Sandborn WJ. PMID: 33819666.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    119. Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply. Aliment Pharmacol Ther. 2021 04; 53(8):957-958. Jangi S, Yoon H, Dulai P, Valasek M, Boland B, Jairath V, Feagan B, Sandborn W, Singh S. PMID: 33745174.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    120. The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice. Gastroenterol Hepatol (N Y). 2021 Apr; 17(4 Suppl 4):3-13. Sandborn WJ, Feagan BG, Hanauer SB, Lichtenstein GR. PMID: 34135718; PMCID: PMC8191814.
      View in: PubMed   Mentions: 6  
    121. Drug development for ulcerative proctitis: current concepts. Gut. 2021 07; 70(7):1203-1209. Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. PMID: 33789968.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    122. Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). Gut. 2022 06; 71(6):1078-1087. Narula N, Wong ECL, Colombel JF, Sandborn WJ, Marshall JK, Daperno M, Reinisch W, Dulai PS. PMID: 33766910.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    123. An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. Aliment Pharmacol Ther. 2021 05; 53(10):1108-1117. Sedano R, Ma C, Pai RK, D' Haens G, Guizzetti L, Shackelton LM, Remillard J, Gionchetti P, Gordon IO, Holubar S, Kayal M, Lauwers GY, Pai RK, Pardi DS, Samaan MA, Schaeffer DF, Shen B, Silverberg MS, Feagan BG, Sandborn WJ, Jairath V. PMID: 33735522.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    124. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. Gastroenterology. 2021 07; 161(1):107-115.e3. Meserve J, Luo J, Zhu W, Veeravalli N, Bandoli G, Chambers CD, Singh AG, Boland BS, Sandborn WJ, Mahadevan U, Singh S. PMID: 33744307; PMCID: PMC8238837.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    125. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2022 03; 20(3):591-601.e8. Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. PMID: 33684552.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    126. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2022 02; 20(2):e74-e88. Singh S, Heien HC, Herrin J, Dulai PS, Sangaralingham L, Shah ND, Sandborn WJ. PMID: 33640480; PMCID: PMC8384969.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    127. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 04; 160(5):1570-1583. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A, International Organization for the Study of IBD. PMID: 33359090.
      View in: PubMed   Mentions: 472     Fields:    Translation:Humans
    128. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 03; 20(3):578-590.e4. Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG, Lynch JP. PMID: 33618023; PMCID: PMC8374005.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    129. An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology. 2021 06; 160(7):2291-2302. Ma C, Sedano R, Almradi A, Vande Casteele N, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R, Sands BE, Rosty C, Dubinsky MC, Rieder F, Harpaz N, Abreu MT, Bryant RV, Lauwers GY, Kirsch R, Valasek MA, Crowley E, Sandborn WJ, Feagan BG, Pai RK, Jairath V. PMID: 33610533; PMCID: PMC8851891.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    130. Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 04; 20(4):e750-e760. Jangi S, Holmer AK, Dulai PS, Boland B, Valasek M, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 33556578; PMCID: PMC9550577.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    131. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev. 2021 03; 10(3):229-240. Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A. PMID: 33513294; PMCID: PMC7986169.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    132. An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. Aliment Pharmacol Ther. 2021 04; 53(7):784-793. Almradi A, Ma C, D'Haens GR, Sandborn WJ, Parker CE, Guizzetti L, Borralho Nunes P, De Hertogh G, Feakins RM, Khanna R, Lauwers GY, Mookhoek A, Pai RK, Peyrin-Biroulet L, Riddell R, Rosty C, Schaeffer DF, Valasek MA, Singh S, Crowley E, Feagan BG, Jairath V, Pai RK. PMID: 33410551.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    133. Routine incorporation of the local read in Crohn's disease clinical trials? Not so fast. Gastrointest Endosc. 2021 01; 93(1):183-186. Jairath V, Zou GY, Ma C, Feagan BG, Sandborn WJ. PMID: 33353616.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    134. A double-blind, 377-subject randomized study identifies Ruminococcus, Coprococcus, Christensenella, and Collinsella as long-term potential key players in the modulation of the gut microbiome of lactose intolerant individuals by galacto-oligosaccharides. Gut Microbes. 2021 Jan-Dec; 13(1):1957536. Azcarate-Peril MA, Roach J, Marsh A, Chey WD, Sandborn WJ, Ritter AJ, Savaiano DA, Klaenhammer TR. PMID: 34365905; PMCID: PMC8354614.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    135. Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. Clin Gastroenterol Hepatol. 2022 01; 20(1):236-238. Hanzel J, Ma C, Zou G, Singh S, Dulai PS, Feagan BG, D'Haens GR, Sandborn WJ, Jairath V. PMID: 33346141.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    136. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 2021 02; 53(3):374-382. Meserve J, Facciorusso A, Holmer AK, Annese V, Sandborn WJ, Singh S. PMID: 33314269; PMCID: PMC8041067.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    137. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 02; 20(2):447-454.e1. Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. PMID: 33279779; PMCID: PMC8588993.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    138. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021 03; 160(4):1131-1139. Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, Cohen RD, Chambers CD, Sandborn WJ, Crohn’s Colitis Foundation Clinical Research Alliance. PMID: 33227283; PMCID: PMC7956164.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    139. Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. Therap Adv Gastroenterol. 2020; 13:1756284820971214. Holmer AK, Battat R, Dulai PS, Vande Casteele N, Nguyen N, Jain A, Miralles A, Neill J, Le H, Singh S, Rivera-Nieves J, Sandborn WJ, Boland BS. PMID: 33240396; PMCID: PMC7675888.
      View in: PubMed   Mentions: 2  
    140. Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. Clin Gastroenterol Hepatol. 2021 10; 19(10):2031-2045.e11. Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, Feagan BG, Jairath V, Sandborn WJ, Singh S. PMID: 33127595; PMCID: PMC8934200.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    141. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 08; 20(8):1821-1830.e3. Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. PMID: 33127596.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    142. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther. 2020 12; 52(11-12):1658-1675. Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Arasaradnam RP, Sands BE, Marano C. PMID: 33086438; PMCID: PMC8776399.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    143. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 01; 20(1):126-135. Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Koliani-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. PMID: 33039584; PMCID: PMC8026779.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    144. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol. 2020 12; 5(12):1063-1075. Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W, CONDUCT study group. PMID: 33031757.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    145. Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Aliment Pharmacol Ther. 2020 11; 52(10):1574-1582. Battat R, Vande Casteele N, Pai RK, Wang Z, Zou G, McDonald JWD, Duijvestein M, Jeyarajah J, Parker CE, Van Viegen T, Nelson SA, Boland BS, Singh S, Dulai PS, Valasek MA, Feagan BG, Jairath V, Sandborn WJ. PMID: 32981088; PMCID: PMC8007067.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    146. Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. Gastroenterology. 2020 12; 159(6):2013-2018.e7. Abreu MT, Sandborn WJ, IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group. PMID: 32961246.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    147. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 01; 20(1):105-115.e14. Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG. PMID: 32950748.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    148. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflamm Bowel Dis. 2020 09 18; 26(10):1562-1571. Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, Travis S, Danese S, Sandborn WJ, Schreiber S, Berg S, Zhou Q, Kligys K, Neimark E, Suleiman AA, D'Haens G, Colombel JF. PMID: 32105310; PMCID: PMC7500520.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    149. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Sep 16; 14(9):1274-1281. Schreiber S, Hanauer SB, Sandborn WJ, Barrett K. PMID: 32179906.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    150. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis. 2020 Sep 16; 14(9):1202-1213. Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J. PMID: 32161949; PMCID: PMC7493219.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCTClinical Trials
    151. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365. Loftus EV, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, Danese S, D'Haens G, Rubin DT, Shafran I, Parfionovas A, Rogers R, Lirio RA, Vermeire S. PMID: 32876349; PMCID: PMC7540482.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    152. Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. Dig Dis Sci. 2021 08; 66(8):2564-2569. Barsky M, Meserve J, Le H, Collins A, Singh S, Boland B, Sandborn WJ, Dulai PS. PMID: 32875527; PMCID: PMC7927417.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    153. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology. 2020 12; 159(6):2052-2064. Li K, Marano C, Zhang H, Yang F, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR, De Hertogh G. PMID: 32853634.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    154. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci Immunol. 2020 08 21; 5(50). Boland BS, He Z, Tsai MS, Olvera JG, Omilusik KD, Duong HG, Kim ES, Limary AE, Jin W, Milner JJ, Yu B, Patel SA, Louis TL, Tysl T, Kurd NS, Bortnick A, Quezada LK, Kanbar JN, Miralles A, Huylebroeck D, Valasek MA, Dulai PS, Singh S, Lu LF, Bui JD, Murre C, Sandborn WJ, Goldrath AW, Yeo GW, Chang JT. PMID: 32826341; PMCID: PMC7733868.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    155. Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2020 08 20; 26(9):1429-1435. Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S. PMID: 31748806; PMCID: PMC7441095.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    156. Frailty Is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 10; 19(10):2054-2063.e14. Qian AS, Nguyen NH, Elia J, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 32801013; PMCID: PMC7930013.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    157. Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. Br J Clin Pharmacol. 2021 03; 87(3):1141-1149. Vande Casteele N, Jakate A, McNamee B, Sandborn WJ. PMID: 32671846; PMCID: PMC9328660.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    158. Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. Aliment Pharmacol Ther. 2020 09; 52(6):1008-1016. Jangi S, Yoon H, Dulai PS, Valasek M, Boland BS, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 33119168; PMCID: PMC8965793.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    159. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis. Gastroenterology. 2021 01; 160(1):115-127.e30. Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson AD, Cook DN, Pomerantz RJ, Misra BK, Auninš JG, Trucksis M. PMID: 32763240; PMCID: PMC7402096.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    160. Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. Aliment Pharmacol Ther. 2020 08; 52(3):568-569. Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. PMID: 32656846.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    161. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Aliment Pharmacol Ther. 2020 08; 52(4):669-681. Bohm M, Xu R, Zhang Y, Varma S, Fischer M, Kochhar G, Boland B, Singh S, Hirten R, Ungaro R, Shmidt E, Lasch K, Jairaith V, Hudesman D, Chang S, Lukin D, Swaminath A, Sands BE, Colombel JF, Kane S, Loftus EV, Shen B, Siegel CA, Sandborn WJ, Dulai PS, VICTORY Collaboration. PMID: 32656800; PMCID: PMC7496810.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    162. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020 08; 52(3):481-491. Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. PMID: 32573825; PMCID: PMC8015755.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    163. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology. 2020 10; 159(4):1262-1275.e7. Yoon H, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 32585306; PMCID: PMC7658293.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    164. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020 09; 5(9):819-828. Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G. PMID: 32553149.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    165. Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 07; 19(7):1377-1386.e5. Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 32526341; PMCID: PMC7987215.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    166. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. Am J Gastroenterol. 2020 06; 115(6):885-894. Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, D'Haens G, Feagan BG, Sandborn WJ, Jairath V, Singh S. PMID: 32384283; PMCID: PMC7274901.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    167. Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply. Aliment Pharmacol Ther. 2020 06; 51(11):1209-1210. Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. PMID: 32424928.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    168. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program. Adv Ther. 2020 07; 37(7):3417-3431. Sandborn WJ, Vermeire S, Tyrrell H, Hassanali A, Lacey S, Tole S, Tatro AR, Etrolizumab Global Steering Committee. PMID: 32445184; PMCID: PMC7467434.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    169. Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 06; 19(6):1170-1179.e10. Dulai PS, Sandborn WJ, Murphy J. PMID: 32437872.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    170. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. Clin Gastroenterol Hepatol. 2021 06; 19(6):1209-1217.e2. Vande Casteele N, Jairath V, Jeyarajah J, Dulai PS, Singh S, Shackelton LM, Feagan BG, Sandborn WJ. PMID: 32376505.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    171. Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Aliment Pharmacol Ther. 2020 05; 51(10):997-998. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. PMID: 32338784.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    172. Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. Am J Gastroenterol. 2020 05; 115(5):738-745. Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Frédéric Colombel J, Rossiter G, Usiskin K, Ather S, Zhan X, D'Haens G. PMID: 31850931.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    173. Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 03; 19(3):511-518.e6. Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, Holmer AK, Nguyen NH, Singh S, Vande Casteele N, Sandborn WJ. PMID: 32348905; PMCID: PMC7606215.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    174. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther. 2020 06; 51(11):1031-1038. Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. PMID: 32329532; PMCID: PMC8032452.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    175. Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2020 06; 51(11):1047-1066. Dulai PS, Jairath V, Khanna R, Ma C, McCarrier KP, Martin ML, Parker CE, Morris J, Feagan BG, Sandborn WJ. PMID: 32319120; PMCID: PMC7317756.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    176. Galacto-Oligosaccharide RP-G28 Improves Multiple Clinical Outcomes in Lactose-Intolerant Patients. Nutrients. 2020 Apr 10; 12(4). Chey W, Sandborn W, Ritter AJ, Foyt H, Azcarate-Peril MA, Savaiano DA. PMID: 32290344; PMCID: PMC7231374.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    177. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. Clin Transl Sci. 2020 07; 13(4):743-751. Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N. PMID: 32100960; PMCID: PMC7359948.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    178. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020 04; 72(4):561-576. Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, Sandborn WJ, Curtis JR. PMID: 30875456; PMCID: PMC6745288.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    179. Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis. 2020 03 04; 26(4):515-523. George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V. PMID: 31504528; PMCID: PMC8127062.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    180. Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. Clin Gastroenterol Hepatol. 2020 10; 18(11):2437-2447.e6. Rozich JJ, Dulai PS, Fumery M, Sandborn WJ, Singh S. PMID: 32142940; PMCID: PMC7490750.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    181. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020 03; 579(7797):123-129. Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy MP, Bodai Z, Belda-Ferre P, Tripathi A, Chung LK, Downes M, Welch RD, Quinn M, Humphrey G, Panitchpakdi M, Weldon KC, Aksenov A, da Silva R, Avila-Pacheco J, Clish C, Bae S, Mallick H, Franzosa EA, Lloyd-Price J, Bussell R, Thron T, Nelson AT, Wang M, Leszczynski E, Vargas F, Gauglitz JM, Meehan MJ, Gentry E, Arthur TD, Komor AC, Poulsen O, Boland BS, Chang JT, Sandborn WJ, Lim M, Garg N, Lumeng JC, Xavier RJ, Kazmierczak BI, Jain R, Egan M, Rhee KE, Ferguson D, Raffatellu M, Vlamakis H, Haddad GG, Siegel D, Huttenhower C, Mazmanian SK, Evans RM, Nizet V, Knight R, Dorrestein PC. PMID: 32103176; PMCID: PMC7252668.
      View in: PubMed   Mentions: 178     Fields:    Translation:HumansAnimals
    182. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology. 2020 06; 158(8):2139-2149.e14. Sandborn WJ, Ghosh S, Panes J, Schreiber S, D'Haens G, Tanida S, Siffledeen J, Enejosa J, Zhou W, Othman AA, Huang B, Higgins PDR. PMID: 32092309.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCTClinical Trials
    183. Host engulfment pathway controls inflammation in inflammatory bowel disease. FEBS J. 2020 09; 287(18):3967-3988. Sayed IM, Suarez K, Lim E, Singh S, Pereira M, Ibeawuchi SR, Katkar G, Dunkel Y, Mittal Y, Chattopadhyay R, Guma M, Boland BS, Dulai PS, Sandborn WJ, Ghosh P, Das S. PMID: 32003126; PMCID: PMC7390677.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    184. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 12; 18(13):2952-2961.e8. Dulai PS, Singh S, Vande Casteele N, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C. PMID: 32062041; PMCID: PMC7899124.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    185. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. 2020 06; 158(8):2123-2138.e8. Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J. PMID: 32044319.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    186. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Clin Ther. 2020 01; 42(1):157-174.e4. Adedokun OJ, Xu Z, Liao S, Strauss R, Reinisch W, Feagan BG, Sandborn WJ. PMID: 31982148.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    187. Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020 04; 5(4):393-405. Shen B, Kochhar G, Navaneethan U, Farraye FA, Schwartz DA, Iacucci M, Bernstein CN, Dryden G, Cross R, Bruining DH, Kobayashi T, Lukas M, Shergill A, Bortlik M, Lan N, Lukas M, Tang SJ, Kotze PG, Kiran RP, Dulai PS, El-Hachem S, Coelho-Prabhu N, Thakkar S, Mao R, Chen G, Zhang S, Suárez BG, Lama YG, Silverberg MS, Sandborn WJ. PMID: 31954438.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    188. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020 09; 18(10):2179-2191.e6. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. PMID: 31945470; PMCID: PMC8022894.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    189. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313. Lewis JD, Rutgeerts P, Feagan BG, D'haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ. PMID: 31644790.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    190. Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid? Curr Treat Options Gastroenterol. 2020 03; 18(1):15-32. Battat R, Dulai PS, Ma C, Jairath V, Feagan BG, Sandborn WJ, Khanna R. PMID: 31902071.
      View in: PubMed   Mentions:
    191. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32. Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S. PMID: 31158271.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    192. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2020 03; 51(5):553-564. Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F, GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*. PMID: 31867766; PMCID: PMC7028036.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    193. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 09; 18(10):2244-2255.e9. Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, Van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ. PMID: 31816446.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    194. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther. 2020 02; 51(4):435-445. Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ. PMID: 31755121; PMCID: PMC6989392.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    195. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):550-561. Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. PMID: 31711921.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    196. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology. 2020 02; 158(3):515-526.e10. D'Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS. PMID: 31711925.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    197. Optimizing sequencing protocols for leaderboard metagenomics by combining long and short reads. Genome Biol. 2019 10 31; 20(1):226. Sanders JG, Nurk S, Salido RA, Minich J, Xu ZZ, Zhu Q, Martino C, Fedarko M, Arthur TD, Chen F, Boland BS, Humphrey GC, Brennan C, Sanders K, Gaffney J, Jepsen K, Khosroheidari M, Green C, Liyanage M, Dang JW, Phelan VV, Quinn RA, Bankevich A, Chang JT, Rana TM, Conrad DJ, Sandborn WJ, Smarr L, Dorrestein PC, Pevzner PA, Knight R. PMID: 31672156; PMCID: PMC6822431.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimals
    198. Positioning Therapies in the Management of Crohn's Disease. Clin Gastroenterol Hepatol. 2020 05; 18(6):1268-1279. Nguyen NH, Singh S, Sandborn WJ. PMID: 31676360; PMCID: PMC7183879.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    199. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther. 2020 01; 51(2):271-280. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. PMID: 31660640; PMCID: PMC9328429.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    200. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 10 18; 25(11):1828-1837. Limketkai BN, Singh S, Jairath V, Sandborn WJ, Dulai PS. PMID: 31039246; PMCID: PMC6799945.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    201. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflamm Bowel Dis. 2019 10 18; 25(11):1854-1861. Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS. PMID: 31050734; PMCID: PMC6799947.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    202. Prevalence of Fistulizing Crohn's Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis. Inflamm Bowel Dis. 2019 10 18; 25(11):1773-1779. Schwartz DA, Tagarro I, Carmen Díez M, Sandborn WJ. PMID: 31216573; PMCID: PMC6799946.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    203. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 11; 50(10):1068-1076. Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. PMID: 31599001; PMCID: PMC6899755.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    204. Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology. 2020 01; 158(1):76-94.e2. Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L. PMID: 31593701.
      View in: PubMed   Mentions: 130     Fields:    Translation:Humans
    205. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1201-1214. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C, UNIFI Study Group. PMID: 31553833.
      View in: PubMed   Mentions: 316     Fields:    Translation:HumansCTClinical Trials
    206. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 07; 18(8):1760-1768.e1. Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. PMID: 31546056; PMCID: PMC7992966.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    207. Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. J Crohns Colitis. 2019 Sep 19; 13(9):1227-1233. Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W. PMID: 30726897; PMCID: PMC6751337.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    208. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019 10; 50(8):848-857. Singh S, Dulai PS, Vande Casteele N, Battat R, Fumery M, Boland BS, Sandborn WJ. PMID: 31483522; PMCID: PMC7083298.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    209. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):537-549.e10. Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR. PMID: 31493397.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    210. Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. Clin Gastroenterol Hepatol. 2020 08; 18(9):2139-2141.e2. Ma C, Gecse KB, Duijvestein M, Sandborn WJ, Zou G, Shackelton LM, Stitt LW, Parker CE, Bossuyt P, Löwenberg M, Khanna R, Vermeire S, Rutgeerts P, Feagan BG, Jairath V, D'Haens GR. PMID: 31473359.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    211. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):562-572.e12. Sandborn WJ, Baert F, Danese S, Krznaric Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. PMID: 31470005.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCTClinical Trials
    212. Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020 08; 18(9):1939-1948.e7. Nguyen NH, Koola J, Dulai PS, Prokop LJ, Sandborn WJ, Singh S. PMID: 31470176; PMCID: PMC7044053.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    213. Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. Clin Gastroenterol Hepatol. 2020 05; 18(5):1121-1132.e2. Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, VandeCasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D'Haens GR, Jairath V. PMID: 31442599.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    214. Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2019 08 20; 25(9):1532-1540. Adedokun OJ, Gunn GR, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P, Shankar G. PMID: 30753466.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    215. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs. 2019 Aug; 79(12):1321-1335. Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. PMID: 31317509.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    216. Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. Gastroenterology. 2019 11; 157(5):1233-1244.e5. Hindryckx P, Jairath V, Zou G, Feagan BG, Sandborn WJ, Stoker J, Khanna R, Stitt L, van Viegen T, Shackelton LM, Taylor SA, Santillan C, Mearadji B, D'Haens G, Richard MP, Panes J, Rimola J. PMID: 31336124.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    217. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. Gastroenterology. 2019 10; 157(4):1019-1031.e7. Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, Feagan BG, Sandborn WJ, Rutgeerts P, De Hertogh G. PMID: 31279870.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    218. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology. 2019 10; 157(4):1007-1018.e7. Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. PMID: 31279871.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    219. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2019 10; 157(4):1032-1043.e1. Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ. PMID: 31228441.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    220. Correction: Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2019 06; 114(6):1011. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 31033518.
      View in: PubMed   Mentions:    Fields:    
    221. Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2019 06; 114(6):1010. Singh S, Proudfoot J, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. PMID: 31033520.
      View in: PubMed   Mentions:    Fields:    
    222. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019; 5(1):e000942. Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, Winthrop K, de Longueville M, Huybrechts I, Bykerk VP. PMID: 31245056; PMCID: PMC6560674.
      View in: PubMed   Mentions: 25  Translation:Humans
    223. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. J Crohns Colitis. 2019 May 27; 13(6):725-734. Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF. PMID: 30753371; PMCID: PMC6535500.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    224. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 02; 18(2):424-431.e7. Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V. PMID: 31108227; PMCID: PMC6858937.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    225. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2019 05; 114(5):733-745. Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Vande Casteele N, Pai RK, Feagan BG, Sandborn WJ, Jairath V. PMID: 30694863.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    226. Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? Clin Gastroenterol Hepatol. 2019 12; 17(13):2634-2643. Dulai PS, Singh S, Vande Casteele N, Boland BS, Rivera-Nieves J, Ernst PB, Eckmann L, Barrett KE, Chang JT, Sandborn WJ. PMID: 31009791; PMCID: PMC6885453.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    227. Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. Aliment Pharmacol Ther. 2019 06; 49(11):1401-1409. Novak G, Stevens T, Van Viegen T, Bossuyt P, Štabuc B, Jeyarajah J, Zou G, Gaemers IC, McKee TD, Fu F, Shackelton LM, Khanna R, van den Brink GR, Sandborn WJ, Feagan BG, Pai RK, Jairath V, Vande Casteele N, D'Haens G. PMID: 30983024.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    228. Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases. Am J Gastroenterol. 2019 04; 114(4):630-639. Jain A, Nguyen NH, Proudfoot JA, Martin CF, Sandborn WJ, Kappelman MD, Long MD, Singh S. PMID: 30865012; PMCID: PMC6824268.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    229. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. Dig Dis Sci. 2019 09; 64(9):2478-2488. Dulai PS, Osterman MT, Lasch K, Cao C, Riaz F, Sandborn WJ. PMID: 30923985; PMCID: PMC6704097.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    230. Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 2019 05; 49(9):1188-1194. Singh S, Stitt LW, Zou G, Khanna R, Dulai PS, Sandborn WJ, Feagan BG, Jairath V. PMID: 30891808; PMCID: PMC6461484.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    231. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol. 2019; 10:212. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. PMID: 30930775; PMCID: PMC6425155.
      View in: PubMed   Mentions: 38  
    232. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020 01; 18(1):69-81.e3. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. PMID: 30876964; PMCID: PMC8011651.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    233. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis. 2019 Feb 01; 13(2):172-181. Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. PMID: 30285104; PMCID: PMC6357899.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    234. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflamm Bowel Dis. 2019 01 10; 25(2):410-420. Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS. PMID: 30295781; PMCID: PMC6327228.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    235. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis. 2019 01 10; 25(2):270-282. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. PMID: 30165490; PMCID: PMC6327230.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    236. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 11; 17(12):2497-2505.e1. Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV, Sands BE, Colombel JF, Dulai PS, Ungaro R. PMID: 30625408; PMCID: PMC7026826.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    237. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57. Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. PMID: 30203005; PMCID: PMC6302953.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    238. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflamm Bowel Dis. 2019 01 01; 25(1):163-171. Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F. PMID: 29982631.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    239. Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Dec; 113(12):696. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. PMID: 30390030; PMCID: PMC6455086.
      View in: PubMed   Mentions: 1     Fields:    
    240. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 11 29; 24(12):2527-2542. Hemperly A, Sandborn WJ, Vande Casteele N. PMID: 29788338.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    241. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2019 03; 156(4):946-957.e18. Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W. PMID: 30472236.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    242. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019 07; 17(8):1541-1550. Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G. PMID: 30476584.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCTClinical Trials
    243. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019 12; 17(13):2722-2730.e4. Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M, Jain A, Sandborn WJ, Boland BS. PMID: 30448597; PMCID: PMC6520204.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    244. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. J Crohns Colitis. 2018 Nov 09; 12(10):1158-1169. Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, Szapary P, Johanns J, Panes J, Vermeire S, O'Brien CD, Yang Z, Bertelsen K, Marano C, Peficitinib-UC Study Group. PMID: 29917064.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    245. Metagenomics-Based, Strain-Level Analysis of Escherichia coli From a Time-Series of Microbiome Samples From a Crohn's Disease Patient. Front Microbiol. 2018; 9:2559. Fang X, Monk JM, Nurk S, Akseshina M, Zhu Q, Gemmell C, Gianetto-Hill C, Leung N, Szubin R, Sanders J, Beck PL, Li W, Sandborn WJ, Gray-Owen SD, Knight R, Allen-Vercoe E, Palsson BO, Smarr L. PMID: 30425690; PMCID: PMC6218438.
      View in: PubMed   Mentions: 28  
    246. Definitions of response and remission for the Robarts Histopathology Index. Gut. 2019 11; 68(11):2101-2102. Pai RK, Khanna R, D'Haens GR, Sandborn WJ, Jeyarajah J, Feagan BG, Vande Casteele N, Jairath V. PMID: 30366909.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    247. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1814-1821.e1. Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ. PMID: 30613004.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    248. Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2019 02; 64(2):382-390. Ahmad W, Nguyen NH, Boland BS, Dulai PS, Pride DT, Bouland D, Sandborn WJ, Singh S. PMID: 30361807; PMCID: PMC6358459.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    249. Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. Gastrointest Endosc. 2019 02; 89(2):215-237. Shen B, Kochhar G, Navaneethan U, Liu X, Farraye FA, Gonzalez-Lama Y, Bruining D, Pardi DS, Lukas M, Bortlik M, Wu K, Sood A, Schwartz DA, Sandborn WJ, Global Interventional Inflammatory Bowel Disease Group. PMID: 30365985.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    250. A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. Lancet Gastroenterol Hepatol. 2019 Jan; 4(1):63-70. Jairath V, Jeyarajah J, Zou G, Parker CE, Olson A, Khanna R, D'Haens GR, Sandborn WJ, Feagan BG. PMID: 30343116.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    251. Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2366-2376. Tyler CJ, Pérez-Jeldres T, Ehinger E, Capaldo B, Karuppuchamy T, Boyer JD, Patel D, Dulai P, Boland BS, Lannigan J, Eckmann L, Ernst PB, Sandborn WJ, Ho SB, Rivera-Nieves J. PMID: 29889233; PMCID: PMC6185553.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    252. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2461-2467. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. PMID: 29788240; PMCID: PMC6693035.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    253. Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 03; 17(4):709-718.e7. Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 30012429.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    254. Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 07; 17(8):1533-1540.e2. Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. PMID: 30268561; PMCID: PMC6594363.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    255. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1. Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. PMID: 30267864.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    256. Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. Clin Gastroenterol Hepatol. 2019 01; 17(2):218-230. Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R. PMID: 30240894; PMCID: PMC6391518.
      View in: PubMed   Mentions: 106     Fields:    Translation:Humans
    257. Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials. Inflamm Bowel Dis. 2018 09 15; 24(10):2278-2284. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 29788260; PMCID: PMC6140448.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    258. Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death. Proc Natl Acad Sci U S A. 2018 09 25; 115(39):E9192-E9200. Garcia-Carbonell R, Wong J, Kim JY, Close LA, Boland BS, Wong TL, Harris PA, Ho SB, Das S, Ernst PB, Sasik R, Sandborn WJ, Bertin J, Gough PJ, Chang JT, Kelliher M, Boone D, Guma M, Karin M. PMID: 30209212; PMCID: PMC6166836.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimalsCells
    259. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42. Hanauer SB, Sandborn WJ, Lichtenstein GR. PMID: 30195449.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    260. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis. 2018 Aug 29; 12(9):1021-1029. Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. PMID: 29767728; PMCID: PMC6113706.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    261. Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. J Crohns Colitis. 2018 Aug 29; 12(9):1053-1066. Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C. PMID: 29917070.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    262. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology. 2018 10; 155(4):1045-1058. Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ. PMID: 29909019.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    263. Project Sonar: A Community Practice-based Intensive Medical Home for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 12; 16(12):1847-1850.e1. Singh S, Brill JV, Proudfoot JA, Metcalfe L, Vu L, Sandborn WJ, Kosinski LR. PMID: 30149146.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    264. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 11; 3(11):742-753. Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. PMID: 30122356; PMCID: PMC6821871.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    265. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 08 16; 24(9):1876-1882. Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A. PMID: 29668916.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    266. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 2019 07; 68(7):1162-1168. Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK. PMID: 30076171.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    267. The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease. J Crohns Colitis. 2018 Jul 30; 12(8):883-895. Sands BE, Han C, Gasink C, Jacobstein D, Szapary P, Gao LL, Lang Y, Targan S, Sandborn WJ, Feagan BG. PMID: 29726939.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    268. Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. J Crohns Colitis. 2018 Jul 30; 12(8):930-938. Panaccione R, Sandborn WJ, D'Haens G, Wolf DC, Berg S, Maa JF, Petersson J, Robinson AM. PMID: 29697818; PMCID: PMC6065484.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    269. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018 10; 3(10):671-680. Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO. PMID: 30056030.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    270. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018 11; 113(11):1678-1688. Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. PMID: 30022113.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansPHPublic Health
    271. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology. 2018 10; 155(4):1008-1011.e8. Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE. PMID: 29981298.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    272. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 09; 113(9):1345. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. PMID: 29946178; PMCID: PMC6445254.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    273. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018 08; 113(8):1197-1205. Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. PMID: 29925913; PMCID: PMC7107271.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    274. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. Aliment Pharmacol Ther. 2018 08; 48(3):347-357. Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V. PMID: 29920726; PMCID: PMC6043370.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    275. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018 08; 48(4):394-409. Singh S, Fumery M, Sandborn WJ, Murad MH. PMID: 29920733.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    276. Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2018 06; 113(6):883-889. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 29867171; PMCID: PMC7107273.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    277. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 2018 09; 155(3):687-695.e10. Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C. PMID: 29857091; PMCID: PMC6419724.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    278. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018 May 25; 12(6):635-643. Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. PMID: 29370397; PMCID: PMC7189966.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    279. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 07; 48(1):65-77. Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. PMID: 29797519; PMCID: PMC6032827.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    280. Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. Inflamm Bowel Dis. 2018 05 18; 24(6):1316-1320. Fumery M, Patel NS, Boland BS, Dulai PS, Singh S, Sandborn WJ. PMID: 29697797; PMCID: PMC6231369.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    281. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018; 13(5):e0195123. Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ. PMID: 29771924; PMCID: PMC5957395.
      View in: PubMed   Mentions: 101     Fields:    Translation:Humans
    282. A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease. Gastroenterol Hepatol (N Y). 2018 May; 14(5 Suppl 2):1-12. Sandborn WJ, Abreu MT, Dubinsky MC. PMID: 29991933; PMCID: PMC6018319.
      View in: PubMed   Mentions: 5  
    283. Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2018 04 27; 12(5):631. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. PMID: 29566131.
      View in: PubMed   Mentions:    Fields:    
    284. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther. 2018 06; 47(12):1578-1596. Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. PMID: 29696670.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    285. Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data. Inflamm Bowel Dis. 2018 04 23; 24(5):932-942. Feagan B, Sandborn WJ, Rutgeerts P, Levesque BG, Khanna R, Huang B, Zhou Q, Maa JF, Wallace K, Lacerda A, Thakkar RB, Robinson AM. PMID: 29668919.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    286. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018 06; 47(11):1472-1479. Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, Vande Casteele N, Evans E, Grunvald EL, Zarrinpar A, Sandborn WJ, Singh S. PMID: 29665045; PMCID: PMC5992082.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    287. Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. Gastrointest Endosc. 2018 08; 88(2):360-369.e2. Samaan MA, Shen B, Mosli MH, Zou G, Sandborn WJ, Shackelton LM, Nelson S, Stitt L, Bloom S, Pardi DS, Gionchetti P, Lindsay J, Travis S, Hart A, Silverberg MS, Feagan BG, D'Haens GR, Jairath V. PMID: 29660321.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    288. Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series. Am J Gastroenterol. 2018 04; 113(4):627-629. Park S, Evans E, Sandborn WJ, Boland B. PMID: 29610516.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    289. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87. Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L. PMID: 29601825.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    290. Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2018 03 28; 12(4):510. Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. PMID: 29385425.
      View in: PubMed   Mentions: 1     Fields:    
    291. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018 09; 16(9):1407-1419.e22. Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. PMID: 29596987.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    292. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. Inflamm Bowel Dis. 2018 03 19; 24(4):871-876. Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochhar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV. PMID: 29509927.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    293. Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2018 03 19; 24(4):916-923. Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 29562273.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    294. Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2018 Mar; 16(1):129-146. Duijvestein M, Battat R, Vande Casteele N, D'Haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG. PMID: 29411220.
      View in: PubMed   Mentions: 32  
    295. Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases. Clin Gastroenterol Hepatol. 2018 08; 16(8):1284-1292.e30. Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 29474966; PMCID: PMC6056327.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    296. Reliability of histologic assessment in patients with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018 Apr; 47(7):940-950. Warners MJ, Ambarus CA, Bredenoord AJ, Verheij J, Lauwers GY, Walsh JC, Katzka DA, Nelson S, van Viegen T, Furuta GT, Gupta SK, Stitt L, Zou G, Parker CE, Shackelton LM, D Haens GR, Sandborn WJ, Dellon ES, Feagan BG, Collins MH, Jairath V, Pai RK. PMID: 29460418.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    297. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 02 15; 24(3):490-501. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Langholff W, Sandborn WJ. PMID: 29462395; PMCID: PMC6176880.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    298. Tracking Human Gut Microbiome Changes Resulting from a Colonoscopy. Methods Inf Med. 2017; 56(6):442-447. Smarr L, Hyde ER, McDonald D, Sandborn WJ, Knight R. PMID: 29582916.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    299. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 05; 154(6):1660-1671. Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. PMID: 29409871.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    300. Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. J Crohns Colitis. 2018 Jan 24; 12(2):167-177. Guizzetti L, Zou G, Khanna R, Dulai PS, Sandborn WJ, Jairath V, Feagan BG. PMID: 29028958; PMCID: PMC5881746.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    301. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study. J Crohns Colitis. 2018 Jan 24; 12(2):188-196. D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O. PMID: 28961770; PMCID: PMC5881743.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    302. Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther. 2018 Mar; 47(6):773-783. Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L. PMID: 29349829.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    303. Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. Clin Transl Gastroenterol. 2018 Jan 18; 9(1):e132. Moustafa A, Li W, Anderson EL, Wong EHM, Dulai PS, Sandborn WJ, Biggs W, Yooseph S, Jones MB, Venter JC, Nelson KE, Chang JT, Telenti A, Boland BS. PMID: 29345635; PMCID: PMC5795019.
      View in: PubMed   Mentions: 49     Fields:    
    304. Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. Inflamm Bowel Dis. 2018 01 18; 24(2):277-285. Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. PMID: 29361090.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    305. Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. Inflamm Bowel Dis. 2018 01 18; 24(2):440-449. Jairath V, Ordas I, Zou G, Panes J, Stoker J, Taylor SA, Santillan C, Horsthuis K, Samaan MA, Shackelton LM, Stitt LW, Hindryckx P, Khanna R, Sandborn WJ, D'Haens G, Feagan BG, Levesque BG, Rimola J. PMID: 29361096.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    306. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Radiology. 2018 Mar; 286(3):776-799. Bruining DH, Zimmermann EM, Loftus EV, Sandborn WJ, Sauer CG, Strong SA, Society of Abdominal Radiology Crohn’s Disease-Focused Panel. PMID: 29319414.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    307. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Gastroenterology. 2018 Mar; 154(4):1172-1194. Bruining DH, Zimmermann EM, Loftus EV, Sandborn WJ, Sauer CG, Strong SA, Society of Abdominal Radiology Crohn’s Disease-Focused Panel. PMID: 29329905.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    308. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? J Crohns Colitis. 2018 Jan 05; 12(1):105-119. Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG. PMID: 28961959.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    309. Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 12 04; 11(12):1510. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. PMID: 28453665; PMCID: PMC5951008.
      View in: PubMed   Mentions:    Fields:    
    310. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):162-175. Singh S, Fumery M, Sandborn WJ, Murad MH. PMID: 29205406.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    311. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet. 2017 12; 56(12):1513-1523. Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. PMID: 28353055.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    312. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Aliment Pharmacol Ther. 2018 01; 47(2):229-237. Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ. PMID: 29159893; PMCID: PMC5765392.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    313. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228. Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H. PMID: 29159817.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    314. Population Health Management for Inflammatory Bowel Disease. Gastroenterology. 2018 01; 154(1):37-45. Dulai PS, Singh S, Ohno-Machado L, Sandborn WJ. PMID: 29122544.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    315. Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. Clin Transl Gastroenterol. 2017 Nov 02; 8(11):e126. Westera L, van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink GR, Cremer J, Danese S, D'Haens G, Eckmann L, Faubion W, Filice M, Korf H, McGovern D, Panes J, Salas A, Sandborn WJ, Silverberg MS, Smith MI, Vermeire S, Vetrano S, Shackelton LM, Stitt L, Jairath V, Levesque BG, Spencer DM, Feagan BG, Vande Casteele N. PMID: 29095427; PMCID: PMC5717516.
      View in: PubMed   Mentions: 4     Fields:    
    316. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017 12 23; 390(10114):2779-2789. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. PMID: 29096949.
      View in: PubMed   Mentions: 255     Fields:    Translation:HumansCTClinical Trials
    317. Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. Am J Gastroenterol. 2017 Nov; 112(11):1658-1669. Warners MJ, Hindryckx P, Levesque BG, Parker CE, Shackelton LM, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Bredenoord AJ, Jairath V. PMID: 29039850.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    318. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut. 2018 10; 67(10):1824-1835. Sandborn WJ, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Reinisch W, Hébuterne X, Park DI, Schreiber S, Nayak S, Ahmad A, Banerjee A, Brown LS, Cataldi F, Gorelick KJ, Cheng JB, Hassan-Zahraee M, Clare R, D'Haens GR. PMID: 28982740; PMCID: PMC6145284.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    319. Endoscopy in inflammatory bowel disease: advances in dysplasia detection and management. Gastrointest Endosc. 2017 12; 86(6):962-971. Kaltenbach T, Sandborn WJ. PMID: 28987547.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    320. Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation. Am J Gastroenterol. 2017 10; 112(10):1621. Boland BS, Riedl MA, Valasek MA, Crowe SE, Sandborn WJ. PMID: 28978958; PMCID: PMC6389596.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    321. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev. 2017 09 08; 9:CD011572. Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. PMID: 28886205; PMCID: PMC6483671.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    322. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. Gastroenterol Clin North Am. 2017 09; 46(3):603-626. Deepak P, Sandborn WJ. PMID: 28838418.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    323. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2018 05; 16(5):637-647.e13. Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. PMID: 28843356.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    324. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 08 03; 377(5):496-7. Sandborn WJ, Su C, Panes J. PMID: 28767341.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    325. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2017 Aug 01; 11(8):921-929. Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. PMID: 28333288.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    326. Histologic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2017 Jul 21; 7:CD012351. Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R. PMID: 28731502; PMCID: PMC6483549.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    327. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. PMID: 28333362; PMCID: PMC5881669.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    328. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Inflamm Bowel Dis. 2017 07; 23(7):1047-1056. Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG. PMID: 28410341.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    329. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. J Crohns Colitis. 2017 Jul 01; 11(7):811-819. Sandborn WJ, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A. PMID: 28333187.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    330. The development of a magnetic resonance imaging index for fistulising Crohn's disease. Aliment Pharmacol Ther. 2017 09; 46(5):516-528. Samaan MA, Puylaert CAJ, Levesque BG, Zou GY, Stitt L, Taylor SA, Shackelton LM, Vandervoort MK, Khanna R, Santillan C, Rimola J, Hindryckx P, Nio CY, Sandborn WJ, D'Haens G, Feagan BG, Jairath V, Stoker J. PMID: 28653753.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    331. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018 03; 16(3):343-356.e3. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. PMID: 28625817; PMCID: PMC6658168.
      View in: PubMed   Mentions: 134     Fields:    Translation:Humans
    332. Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open. 2017 06 09; 7(6):e016146. Ma C, Panaccione R, Fedorak RN, Parker CE, Khanna R, Levesque BG, Sandborn WJ, Feagan BG, Jairath V. PMID: 28601837; PMCID: PMC5726090.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    333. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017 08; 46(3):292-302. D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. PMID: 28568974.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    334. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 07 08; 390(10090):135-144. Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W. PMID: 28527704.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    335. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 05 04; 376(18):1723-1736. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J, OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. PMID: 28467869.
      View in: PubMed   Mentions: 485     Fields:    Translation:HumansCTClinical Trials
    336. Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 06; 112(6):975. Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. PMID: 28417993.
      View in: PubMed   Mentions: 3     Fields:    
    337. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017 04 29; 389(10080):1699-1709. Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. PMID: 28411872.
      View in: PubMed   Mentions: 173     Fields:    Translation:HumansCTClinical Trials
    338. Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. J Crohns Colitis. 2017 Apr 01; 11(4):425-434. Reinisch W, Colombel JF, D'Haens G, Sandborn WJ, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R. PMID: 27815351; PMCID: PMC5881717.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    339. Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424. Vermeire S, Loftus EV, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. PMID: 27683798.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    340. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr 01; 11(4):400-411. Loftus EV, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. PMID: 27683800.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    341. Head-to-head Comparative Studies: Challenges and Opportunities? J Crohns Colitis. 2017 Mar 01; 11(suppl_2):S567-S575. Peyrin-Biroulet L, Lopez A, Sandborn W. PMID: 27660343.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    342. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017 04; 45(8):1058-1072. Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-Biroulet L. PMID: 28247573.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    343. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 06; 66(6):1049-1059. Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. PMID: 28209624; PMCID: PMC5532457.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCTClinical Trials
    344. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. Aliment Pharmacol Ther. 2017 04; 45(8):1021-1042. Jairath V, Zou G, Parker CE, MacDonald JK, Mosli MH, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Kherad O, Koutsoumpas A, Minas E, Restellini S, Samaan MA, Khanna R, Levesque BG, D'Haens G, Sandborn WJ, Feagan BG. PMID: 28164348.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    345. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017 03; 45(5):617-630. Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. PMID: 28074618; PMCID: PMC6658182.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    346. Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 Oct; 112(10):1584-1592. Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. PMID: 28071654.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    347. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis. 2017 01; 23(1):97-106. Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. PMID: 27930408.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    348. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol. 2017 Jun; 15(6):850-856. Cotter TG, Gathaiya N, Catania J, Loftus EV, Tremaine WJ, Baddour LM, Harmsen WS, Zinsmeister AR, Sandborn WJ, Limper AH, Pardi DS. PMID: 28013116; PMCID: PMC5440197.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    349. Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. Gut. 2018 03; 67(3):441-446. Cotter TG, Binder M, Loftus EV, Abboud R, McNally MA, Smyrk TC, Tremaine WJ, Sandborn WJ, Pardi DS. PMID: 27965284.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    350. Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther. 2017 02; 45(3):381-390. Fumery M, Dulai PS, Meirick P, Farrell AM, Ramamoorthy S, Sandborn WJ, Singh S. PMID: 27928830; PMCID: PMC5253136.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    351. Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 May; 15(5):665-674.e5. Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn WJ, Singh S. PMID: 27916678; PMCID: PMC5401779.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    352. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):110-121. Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. PMID: 27899815; PMCID: PMC5550405.
      View in: PubMed   Mentions: 122     Fields:    Translation:Humans
    353. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 11 17; 375(20):1946-1960. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P, UNITI–IM-UNITI Study Group. PMID: 27959607.
      View in: PubMed   Mentions: 567     Fields:    Translation:HumansCTClinical Trials
    354. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther. 2017 01; 45(1):50-62. Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB. PMID: 27883215; PMCID: PMC5157781.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    355. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 11; 22(11):2711-2723. Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B. PMID: 27585411.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    356. Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut. 2018 01; 67(1):61-69. Hindryckx P, Levesque BG, Holvoet T, Durand S, Tang CM, Parker C, Khanna R, Shackelton LM, D'Haens G, Sandborn WJ, Feagan BG, Lebwohl B, Leffler DA, Jairath V. PMID: 27799282.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    357. Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. World J Gastroenterol. 2016 Oct 28; 22(40):8999-9011. Arulanandan A, Dulai PS, Singh S, Sandborn WJ, Kalmaz D. PMID: 27833391; PMCID: PMC5083805.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    358. Development of an index to define overall disease severity in IBD. Gut. 2018 02; 67(2):244-254. Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. PMID: 27780886.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    359. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017 02; 152(2):374-388.e4. Abraham C, Dulai PS, Vermeire S, Sandborn WJ. PMID: 27780712; PMCID: PMC5287922.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    360. Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila). 2016 Dec; 9(12):887-894. Dulai PS, Sandborn WJ, Gupta S. PMID: 27679553; PMCID: PMC5289746.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    361. Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. Am J Gastroenterol. 2016 12; 111(12):1806-1815. Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD. PMID: 27670599.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    362. Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2016 Sep; 18(9):51. Dulai PS, Sandborn WJ. PMID: 27461274; PMCID: PMC5901649.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    363. Ozanimod Treatment for Ulcerative Colitis. N Engl J Med. 2016 08 25; 375(8):e17. Sandborn WJ, Feagan BG. PMID: 27557326.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    364. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol. Curr Med Res Opin. 2016 12; 32(12):1937-1941. Melmed GY, McGovern D, Schreiber S, Kosutic G, Spearman M, Coarse J, Sandborn WJ. PMID: 27494777.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    365. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2016 Aug 08; (8):CD010642. Khanna R, Nelson SA, Feagan BG, D'Haens G, Sandborn WJ, Zou GY, MacDonald JK, Parker CE, Jairath V, Levesque BG. PMID: 27501379; PMCID: PMC7079710.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    366. Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2017 02; 11(2):246-255. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. PMID: 27487793.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    367. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6. Bosworth BP, Sandborn WJ, Rubin DT, Harper JR. PMID: 27416045; PMCID: PMC4949012.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    368. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80. Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. PMID: 27400222; PMCID: PMC4949014.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    369. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clin Gastroenterol Hepatol. 2016 09; 14(9):e121-2. Sandborn W, Colombel JF, D'Haens G, Ghosh S, Panaccione R, Panés J, Travis S, Peyrin-Biroulet L. PMID: 27464592.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    370. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis. 2017 Jan; 11(1):35-46. Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P, Sandborn WJ. PMID: 27440869; PMCID: PMC5175493.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    371. Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. J Crohns Colitis. 2016 Sep; 10(9):1006-14. Dubcenco E, Zou G, Stitt L, Baker JP, Jeejeebhoy KN, Kandel G, Kim YI, Grover SC, McDonald JW, Shackelton LM, Khanna R, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG. PMID: 27385400.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    372. The Present and Future of Inflammatory Bowel Disease Treatment. Gastroenterol Hepatol (N Y). 2016 Jul; 12(7):438-41. Sandborn WJ. PMID: 27489526; PMCID: PMC4969780.
      View in: PubMed   Mentions: 17  
    373. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. Inflamm Bowel Dis. 2016 07; 22(7):1737-43. Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG. PMID: 27306074.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    374. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol. 2016 08; 111(8):1147-55. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. PMID: 27296941.
      View in: PubMed   Mentions: 111     Fields:    Translation:Humans
    375. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016 07; 44(2):157-69. Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. PMID: 27218676; PMCID: PMC5089609.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    376. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol. 2016 09; 14(9):1302-9. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. PMID: 27189916.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    377. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016 May 05; 374(18):1754-62. Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A, TOUCHSTONE Study Group. PMID: 27144850.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCTClinical Trials
    378. Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2016 10; 14(10):1439-44. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV. PMID: 27155552; PMCID: PMC5028241.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    379. Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis. Am J Gastroenterol. 2016 05; 111(5):746-8. Boland BS, Bagi P, Valasek MA, Chang JT, Bustamante R, Madlensky L, Sandborn WJ, Harismendy O, Gupta S. PMID: 27151126; PMCID: PMC5824983.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    380. Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clin Transl Gastroenterol. 2016 Apr 28; 7:e168. Gibson PR, Feagan BG, Sandborn WJ, Marano C, Strauss R, Johanns J, Padgett L, Collins J, Tarabar D, Hebzda Z, Rutgeerts P, Reinisch W. PMID: 27124701; PMCID: PMC4855165.
      View in: PubMed   Mentions: 16     Fields:    
    381. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr; 22(4):998-1009. Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. PMID: 26835982; PMCID: PMC5953904.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    382. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016 07; 32(7):1233-41. Sandborn WJ, Sakuraba A, Wang A, Macaulay D, Reichmann W, Wang S, Chao J, Skup M. PMID: 26986449.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    383. Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology. 2016 05; 150(5):1056-1060. Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG. PMID: 27018491.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    384. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P, PREVENT Study Group. PMID: 26946343.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansPHPublic Health
    385. Reply. Gastroenterology. 2016 Apr; 150(4):1039. Jharap B, Colombel JF, Sandborn WJ. PMID: 26926449.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    386. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017 05; 66(5):839-851. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. PMID: 26893500; PMCID: PMC5531223.
      View in: PubMed   Mentions: 279     Fields:    Translation:Humans
    387. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):638-9. D'Haens G, Bressler B, Danese S, Gibson P, Hanauer SB, Sandborn W. PMID: 26850690.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    388. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016 Mar; 15(3):173-83. Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. PMID: 26822833; PMCID: PMC4890615.
      View in: PubMed   Mentions: 176     Fields:    Translation:HumansAnimalsCells
    389. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016 May; 10(5):607-18. Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Koutsoumpas A, Minas E, Samaan MA, Travis S, D'Haens G, Levesque BG, Sandborn WJ, Feagan BG. PMID: 26746169; PMCID: PMC4957452.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    390. Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. J Crohns Colitis. 2016 Apr; 10(4):418-28. Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A. PMID: 26721935; PMCID: PMC4946756.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    391. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017 04; 66(4):588-596. Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L, International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group, International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. PMID: 26646934.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    392. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? Inflamm Bowel Dis. 2015 Dec; 21(12):2948-57. Chande N, Marshall JK, Seow CH, Sandborn WJ, Parker CE, Nelson S, Feagan BG. PMID: 26540276.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    393. The Role of Psychosocial Care in Adapting to Health Care Reform. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2219-24. Reiss M, Sandborn WJ. PMID: 26589873.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    394. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2015 Nov 23; (11):CD001176. Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. PMID: 26593456; PMCID: PMC4917283.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    395. Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation. Aliment Pharmacol Ther. 2016 Jan; 43(1):61-72. Coimbra AJ, Rimola J, O'Byrne S, Lu TT, Bengtsson T, de Crespigny A, Luca D, Rutgeerts P, Bruining DH, Fidler JL, Sandborn WJ, Santillan CS, Higgins PD, Al-Hawary MM, Vermeire S, Vanbeckevoort D, Vanslembrouck R, Peyrin-Biroulet L, Laurent V, Herrmann KA, Panes J. PMID: 26548868.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    396. Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease. Am J Gastroenterol. 2015 Nov; 110(11):1631-2. Boland BS, Dulai PS, Chang M, Sandborn WJ, Levesque BG. PMID: 26618431; PMCID: PMC5824985.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    397. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology. 2016 Feb; 150(2):477-87.e9. Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME. PMID: 26522261.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    398. Development and validation of a histological index for UC. Gut. 2017 01; 66(1):50-58. Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG. PMID: 26475633.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    399. Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. Inflamm Bowel Dis. 2015 Oct; 21(10):2475-82. Gottlieb K, Travis S, Feagan B, Hussain F, Sandborn WJ, Rutgeerts P. PMID: 26086596.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    400. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. Aliment Pharmacol Ther. 2015 Nov; 42(10):1170-81. Feagan BG, Sandborn WJ, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ. PMID: 26400458.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    401. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015 Nov; 42(10):1200-10. Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG. PMID: 26388424.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    402. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17. Rubin DT, Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. PMID: 26386854; PMCID: PMC4621699.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    403. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology. 2016 Jan; 150(1):96-102. Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. PMID: 26376350.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    404. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut. 2016 09; 65(9):1447-55. Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L. PMID: 26353983.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    405. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015 Nov 07; 386(10006):1825-34. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG, REACT Study Investigators. PMID: 26342731.
      View in: PubMed   Mentions: 136     Fields:    Translation:Humans
    406. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015 Nov; 42(9):1082-92. Jharap B, Sandborn WJ, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. PMID: 26381802; PMCID: PMC5049645.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    407. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. PMID: 26303131.
      View in: PubMed   Mentions: 583     Fields:    Translation:Humans
    408. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease. Aliment Pharmacol Ther. 2015 Oct; 42(7):783-92. Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH, Hart AL, Sandborn WJ, Loftus EV. PMID: 26264359; PMCID: PMC6698449.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    409. Reply: To PMID 24036054. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2382. Sandborn WJ, Bouguen G. PMID: 26247165.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    410. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointest Endosc. 2016 Jan; 83(1):188-97.e1-3. Rutgeerts P, Reinisch W, Colombel JF, Sandborn WJ, D'Haens G, Petersson J, Zhou Q, Iezzi A, Thakkar RB. PMID: 26234693.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    411. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015 Sep; 42(5):504-14. Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF, Reinisch W, Gibson PR, Sandborn WJ, PURSUIT-IV study group. PMID: 26119226; PMCID: PMC4755132.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    412. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis. 2015 Sep; 9(9):738-46. Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ. PMID: 26094251; PMCID: PMC4736820.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    413. IBD: Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol. 2015 Jul; 12(7):373-4. Vande Casteele N, Sandborn WJ. PMID: 26077557.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    414. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. PMID: 26071941.
      View in: PubMed   Mentions: 119     Fields:    Translation:Humans
    415. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug; 42(3):330-42. Sandborn WJ, Melmed GY, McGovern DP, Loftus EV, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. PMID: 26031921.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    416. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R. PMID: 25989338; PMCID: PMC4450894.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    417. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1435-42. Vaughn BP, Sandborn WJ, Cheifetz AS. PMID: 25590953; PMCID: PMC4437804.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    418. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015 Aug; 82(2):246-55. Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. PMID: 26005012; PMCID: PMC6709676.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    419. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul; 42(2):188-202. Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I. PMID: 25996351; PMCID: PMC5032981.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCTClinical Trials
    420. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015 Jun; 110(6):802-19; quiz 820. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. PMID: 25964225.
      View in: PubMed   Mentions: 205     Fields:    Translation:Humans
    421. The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015 Aug; 9(8):607-16. Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA, Sandborn WJ. PMID: 25956538; PMCID: PMC4584567.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    422. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut. 2016 07; 65(7):1119-25. Khanna R, Zou G, D'Haens G, Rutgeerts P, McDonald JW, Daperno M, Feagan BG, Sandborn WJ, Dubcenco E, Stitt L, Vandervoort MK, Donner A, Luo A, Levesque BG. PMID: 25935574.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    423. New Targets for Small Molecules in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2015 May; 11(5):338-40. Sandborn WJ. PMID: 27482177; PMCID: PMC4962684.
      View in: PubMed   Mentions: 5  
    424. Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. J Crohns Colitis. 2015 Aug; 9(8):601-6. Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, Peyrin-Biroulet L, Colombel JF. PMID: 25908718.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    425. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. J Clin Pharmacol. 2015 Aug; 55(8):866-74. Wade JR, Parker G, Kosutic G, Feagen BG, Sandborn WJ, Laveille C, Oliver R. PMID: 25735646; PMCID: PMC6680228.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    426. Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions. Expert Rev Clin Immunol. 2015 May; 11(5):637-57. Reinhard A, Sandborn WJ, Melhem H, Bolotine L, Chamaillard M, Peyrin-Biroulet L. PMID: 25837708.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    427. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015 Apr; 35(4):412-23. Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. PMID: 25884529; PMCID: PMC6709861.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    428. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis. 2015 Mar; 21(3):606-14. Bouguen G, Sninsky C, Tang KL, Colombel JF, D'Haens G, Kornbluth A, Mantzaris GJ, Rachmilewitz D, Reinisch W, Rutgeerts P, Molenda M, Jannekevan der Woude C, Sandborn WJ. PMID: 25581826.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    429. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015 Apr; 41(8):734-46. Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ. PMID: 25728587.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    430. Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2015 Mar; 11(3 Suppl 1):1-16. Lichtenstein GR, Hanauer SB, Sandborn WJ. PMID: 26491415; PMCID: PMC4609145.
      View in: PubMed   Mentions: 3  
    431. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015 Mar 05; 519(7541):57-62. Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M. PMID: 25731159; PMCID: PMC4447318.
      View in: PubMed   Mentions: 322     Fields:    Translation:HumansAnimalsCells
    432. Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis. 2015 Apr; 9(4):356-66. Bryant RV, Sandborn WJ, Travis SP. PMID: 25687206.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    433. Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol. 2015 Mar 15; 194(6):2551-60. Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui JD, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C, Sandborn WJ, Murray JA, Harismendy O, Chang JT. PMID: 25667416; PMCID: PMC4355235.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    434. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis. 2015 Feb; 21(2):323-30. Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. PMID: 25545378; PMCID: PMC4404151.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    435. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015 Apr; 148(4):740-750.e2. Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP. PMID: 25644096.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    436. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015 May; 47(5):356-64. Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. PMID: 25661014.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    437. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015 Mar; 41(5):409-18. Sandborn WJ, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S. PMID: 25588902; PMCID: PMC6681012.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    438. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015 Jan; 21(1):182-97. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. PMID: 25222660.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    439. Tailoring treatment to the individual patient: drug monitoring. Dig Dis. 2014; 32 Suppl 1:88-91. Sandborn WJ. PMID: 25531358.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    440. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2014 Nov; 20(11):2092-103. Mojtahed A, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Shackelton LM, Baker KA, Dubcenco E, Valasek MA, Geboes K, Levesque BG. PMID: 25137418.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    441. Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us? Inflamm Bowel Dis. 2014 Nov; 20(11):2132-41. Akobeng AA, Sandborn WJ, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG. PMID: 25299543.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    442. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014 Nov; 20(11):1996-2003. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. PMID: 25192499; PMCID: PMC5557346.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    443. Reproducibility of histological assessments of disease activity in UC. Gut. 2015 Nov; 64(11):1765-73. Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, MacDonald JK, Vandervoort MK, Samaan MA, Geboes K, Valasek MA, Pai R, Langner C, Riddell R, Harpaz N, Sewitch M, Peterson M, Stitt LW, Levesque BG. PMID: 25360036.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    444. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther. 2015 Jan; 41(1):77-86. Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, Rolleri RL, Bortey E, Paterson C, Forbes WP, Levesque BG. PMID: 25348809.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    445. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015 Oct; 64(10):1539-45. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR, Rutgeerts PJ, Gils A, Sandborn WJ, Vermeire S, Feagan BG. PMID: 25336114; PMCID: PMC4602247.
      View in: PubMed   Mentions: 94     Fields:    Translation:Humans
    446. A phase II study of laquinimod in Crohn's disease. Gut. 2015 Aug; 64(8):1227-35. D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG, Laquinimod for Crohn's Disease Investigators. PMID: 25281416; PMCID: PMC4515993.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    447. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. Inflamm Bowel Dis. 2014 Oct; 20(10):1850-61. Khanna R, Bouguen G, Feagan BG, D'Haens G, Sandborn WJ, Dubcenco E, Baker KA, Levesque BG. PMID: 25029615.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    448. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology. 2015 Jan; 148(1):52-63.e3. Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus EV, Louis E, Panés J, Schölmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, Fiorino G, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, Tontini GE, Zagdanski AM, Bonifacio C, Rimola J, Nachury M, Leroy C, Sandborn W, Colombel JF, Cosnes J. PMID: 25241327.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    449. Factors associated with short- and long-term outcomes of therapy for Crohn's disease. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):539-547.e2. Reinisch W, Colombel JF, Sandborn WJ, Mantzaris GJ, Kornbluth A, Adedokun OJ, Miller M, Tang KL, Rutgeerts P, Cornillie F. PMID: 25245629.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    450. An overview of magnetic resonance enterography for Crohn's disease. Dig Dis Sci. 2014 Sep; 59(9):2040-9. Pola S, Santillan C, Levesque BG, Feagan BG, Sandborn WJ. PMID: 24659238.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    451. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014 Dec; 147(6):1296-1307.e5. Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, Johanns J, Zhou H, Davis HM, Cornillie F, Reinisch W. PMID: 25173754.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansCTClinical Trials
    452. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 Nov; 109(11):1771-80. Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB. PMID: 25155227; PMCID: PMC4223868.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    453. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014 Oct; 40(8):903-16. Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. PMID: 25146586.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    454. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015 Jan; 148(1):37-51.e1. Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. PMID: 25127678.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    455. A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):731-8.e1-6; quiz e41. Yadav S, Dave M, Edakkanambeth Varayil J, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sweetser SR, Melton LJ, Sandborn WJ, Loftus EV. PMID: 25130936; PMCID: PMC4326614.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    456. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014 Aug; 20(8):1465-71. Samaan MA, Mosli MH, Sandborn WJ, Feagan BG, D'Haens GR, Dubcenco E, Baker KA, Levesque BG. PMID: 24831558.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    457. Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2014 Aug; 10(8):478-489. Khanna R, Levesque BG, Sandborn WJ, Feagan BG. PMID: 28845139; PMCID: PMC5566190.
      View in: PubMed   Mentions: 2  
    458. Crohn's disease evaluation and treatment: clinical decision tool. Gastroenterology. 2014 Sep; 147(3):702-5. Sandborn WJ. PMID: 25046160.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    459. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep; 40(5):486-97. Wolf D, D'Haens G, Sandborn WJ, Colombel JF, Van Assche G, Robinson AM, Lazar A, Zhou Q, Petersson J, Thakkar RB. PMID: 25041859.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    460. Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep; 40(5):477-85. Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Chang JT. PMID: 25041724; PMCID: PMC4143528.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    461. Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. Am J Gastroenterol. 2014 Jul; 109(7):1083-4. Feagan BG, Colombel JF, Hanauer SB, Parikh A, Rutgeerts P, Sandborn WJ, Sands BE. PMID: 24989100.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    462. Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014 Dec; 63(12):1843-53. Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. PMID: 24970900.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    463. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014 Sep; 43(3):603-17. Boland BS, Sandborn WJ, Chang JT. PMID: 25110261; PMCID: PMC4129380.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    464. Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed. Clin Gastroenterol Hepatol. 2014 Nov; 12(11):1894-6. Vande Casteele N, Sandborn WJ. PMID: 24951843.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    465. Studies in human intestinal tissues: is it time to reemphasize research in human immunology? Gastroenterology. 2014 Jul; 147(1):26-30. Chang JT, Sandborn WJ, Ernst PB. PMID: 24877864.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    466. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. PMID: 24859203.
      View in: PubMed   Mentions: 248     Fields:    Translation:HumansCTClinical Trials
    467. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014 Jul; 109(7):994-1004. Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. PMID: 24842338.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    468. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014 Jul 26; 384(9940):309-18. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. PMID: 24814090.
      View in: PubMed   Mentions: 156     Fields:    Translation:HumansCTClinical Trials
    469. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep; 8(9):927-35. Sandborn WJ, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. PMID: 24713173.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    470. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014 Apr; 16(4):378. Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, Levesque BG. PMID: 24595615.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    471. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1126-35. Levesque BG, Greenberg GR, Zou G, Sandborn WJ, Singh S, Hauenstein S, Ohrmund L, Wong CJ, Stitt LW, Shackelton LM, King D, Lockton S, Ducharme J, Feagan BG. PMID: 24689499.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    472. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014 Mar; 20(3):564-75. Mosli MH, Feagan BG, Sandborn WJ, D'haens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG. PMID: 24412993.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    473. Non-cirrhotic portal hypertension due to 6-mercaptopurine use for Crohn's disease. Dig Dis Sci. 2014 Jul; 59(7):1642-4. Pola S, Boland BS, Lin GY, Kuo A, Sandborn WJ. PMID: 24535249; PMCID: PMC5824981.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    474. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1246-56.e6. Williet N, Sandborn WJ, Peyrin-Biroulet L. PMID: 24534550.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    475. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014 Feb; 20(2):231-9. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. PMID: 24351660.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    476. Taking a closer look at IBD. Gut. 2014 Feb; 63(2):e1. Egan LJ, Sandborn W. PMID: 24381262.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    477. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Sep; 12(9):1485-93.e2. Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W, Study A3921043 Investigators. PMID: 24480677.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansAnimalsCTClinical Trials
    478. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014 Feb; 109(2):212-23. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ. PMID: 24394749.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    479. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014 Apr; 146(4):941-9. Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. PMID: 24361468.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    480. Outcomes of computed tomography and magnetic resonance enterography in clinical practice of inflammatory bowel disease. Dig Dis Sci. 2014 Apr; 59(4):838-49. Patel NS, Pola S, Muralimohan R, Zou GY, Santillan C, Patel D, Levesque BG, Sandborn WJ. PMID: 24323180.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    481. IBD: Measuring what counts--endoscopic assessment in IBD. Nat Rev Gastroenterol Hepatol. 2014 Jan; 11(1):9-10. Khanna R, Levesque BG, Sandborn WJ. PMID: 24296581.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    482. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Jun; 12(6):978-85. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. PMID: 24246770.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    483. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):423-31.e1. Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X. PMID: 24184736.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    484. Azathioprine-induced neuro-psychiatric disorders. J Crohns Colitis. 2014 Feb; 8(2):180. Bouguen G, Evans E, Sandborn WJ. PMID: 24103346.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    485. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):110-118.e3. Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J. PMID: 24067881.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    486. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013 Nov; 38(10):1236-47. Panaccione R, Colombel JF, Sandborn WJ, D'Haens G, Zhou Q, Pollack PF, Thakkar RB, Robinson AM. PMID: 24134498; PMCID: PMC4670480.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    487. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. PMID: 24036054.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansPHPublic Health
    488. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014 Jan; 63(1):88-95. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. PMID: 23974954.
      View in: PubMed   Mentions: 155     Fields:    Translation:Humans
    489. Is there still a role for thiopurines in Crohn's disease? Gastroenterology. 2013 Oct; 145(4):714-6. Rogler G, Sandborn WJ. PMID: 23973853.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    490. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A, GEMINI 1 Study Group. PMID: 23964932.
      View in: PubMed   Mentions: 843     Fields:    Translation:HumansCTClinical Trials
    491. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, GEMINI 2 Study Group. PMID: 23964933.
      View in: PubMed   Mentions: 721     Fields:    Translation:HumansCTClinical Trials
    492. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013 Nov; 145(5):978-986.e5. Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ, International Organization for the Study of Inflammatory Bowel Diseases. PMID: 23954314.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    493. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013 Aug; 19(9):1858-66. Samuel S, Ingle SB, Dhillon S, Yadav S, Harmsen WS, Zinsmeister AR, Tremaine WJ, Sandborn WJ, Loftus EV. PMID: 23660997; PMCID: PMC4526131.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    494. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov; 145(5):987-95. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ. PMID: 23891974.
      View in: PubMed   Mentions: 143     Fields:    Translation:Humans
    495. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Sep; 38(5):447-59. Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, Sy R, Van Assche G, Walters TD, Sandborn WJ, Feagan BG. PMID: 23848220.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    496. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):414-22.e5. Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. PMID: 23856361.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    497. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013 Jul; 19(8):1700-9. Reinisch W, Sandborn WJ, Panaccione R, Huang B, Pollack PF, Lazar A, Thakkar RB. PMID: 23665965.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    498. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis. 2013 Jul; 19(8):1645-53. Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ. PMID: 23598817.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    499. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):96-109.e1. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P, PURSUIT-Maintenance Study Group. PMID: 23770005.
      View in: PubMed   Mentions: 254     Fields:    Translation:HumansCTClinical Trials
    500. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013 Aug; 38(3):255-63. Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. PMID: 23730956.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    501. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):85-95; quiz e14-5. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P, PURSUIT-SC Study Group. PMID: 23735746.
      View in: PubMed   Mentions: 319     Fields:    Translation:HumansCTClinical Trials
    502. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013 Jun; 19(7):1384-9. Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. PMID: 23535248.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    503. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol. 2013 May; 108(5):857-8. Pola S, Fahmy M, Evans E, Tipps A, Sandborn WJ. PMID: 23644970.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    504. Crohn's disease complicated by strictures: a systematic review. Gut. 2013 Jul; 62(7):1072-84. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. PMID: 23626373; PMCID: PMC4884453.
      View in: PubMed   Mentions: 169     Fields:    Translation:Humans
    505. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013 Apr; 19(5):1073-9. Herfarth HH, Katz JA, Hanauer SB, Sandborn WJ, Loftus EV, Sands BE, Galanko JA, Walkup D, Isaacs KL, Martin CF, Sandler RS, Sartor RB. PMID: 23511031; PMCID: PMC4596532.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansPHPublic Health
    506. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis. 2013 Apr; 19(5):1004-9. Sinakos E, Samuel S, Enders F, Loftus EV, Sandborn WJ, Lindor KD. PMID: 23502353.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    507. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013 Jul; 145(1):149-157.e2. Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JWD, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG. PMID: 23528626.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    508. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials. J Crohns Colitis. 2013 Dec; 7(12):958-67. Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R. PMID: 23517933.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    509. Biosimilars in IBD: hope or expectation? Gut. 2013 Jun; 62(6):803-7. Gecse KB, Khanna R, van den Brink GR, Ponsioen CY, Löwenberg M, Jairath V, Travis SP, Sandborn WJ, Feagan BG, D'Haens GR. PMID: 23503043.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    510. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease. Curr Med Res Opin. 2013 May; 29(5):483-93. Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB. PMID: 23438483.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    511. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar; 63(3):442-50. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S, Aranda R, Luo AY. PMID: 23461895; PMCID: PMC3933070.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    512. Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):677-82. Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE, Abraham C, Nusrat A, Jobin C, McCole DF, Siegel CA, Higgins PD, Herfarth HH, Hyams J, Sandborn WJ, Loftus EV, Kappelman MD, Lewis JD, Parkos CA, Sartor RB, Challenges Workgroup. PMID: 23448796; PMCID: PMC3740342.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    513. Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. Inflamm Bowel Dis. 2013 Mar; 19(3):550-3. Abboud R, Pardi DS, Tremaine WJ, Kammer PP, Sandborn WJ, Loftus EV. PMID: 23380937.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    514. Cecal patch manifest as an inflammatory pseudopolyp and characterized by chromoendoscopy. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):E57-8. Fahmy M, Shabaik A, Sandborn WJ. PMID: 22552963.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    515. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014 Mar; 63(3):433-41. Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. PMID: 23436336; PMCID: PMC3933176.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    516. Reply: budesonide. Gastroenterology. 2013 Mar; 144(3):e23-4. Sandborn WJ, Travis S, Ballard D. PMID: 23357061.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    517. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013 Jun; 11(6):654-66. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. PMID: 23357488.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    518. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Mar; 37(5):546-54. Kisiel JB, Yab TC, Nazer Hussain FT, Taylor WR, Garrity-Park MM, Sandborn WJ, Loftus EV, Wolff BG, Smyrk TC, Itzkowitz SH, Rubin DT, Zou H, Mahoney DW, Ahlquist DA. PMID: 23347191; PMCID: PMC3869396.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    519. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013 Apr; 93(4):324-5. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Hicks JK, Schwab M, Klein TE, Clinical Pharmacogenetics Implementation Consortium. PMID: 23422873; PMCID: PMC3604643.
      View in: PubMed   Mentions: 136     Fields:    Translation:Humans
    520. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol. 2013 Feb; 108(2):256-9. Gentile NM, Abdalla AA, Khanna S, Smyrk TC, Tremaine WJ, Faubion WA, Kammer PP, Sandborn WJ, Loftus EV, Pardi DS. PMID: 23295275; PMCID: PMC3575108.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansPHPublic Health
    521. Deep remission: a new concept? Dig Dis. 2012; 30 Suppl 3:107-11. Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ, Panaccione R. PMID: 23295700.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    522. The future of inflammatory bowel disease therapy: where do we go from here? Dig Dis. 2012; 30 Suppl 3:140-4. Sandborn WJ. PMID: 23295705.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    523. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012 Dec; 107(12):1770-6. Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ. PMID: 23211844.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    524. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013 Jan; 37(2):204-13. Sandborn WJ, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD, Thakkar R. PMID: 23173821.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    525. Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2012 Nov; 8(11 Suppl 8):1-20. Lichtenstein GR, Hanauer SB, Sandborn WJ. PMID: 24847181; PMCID: PMC4027896.
      View in: PubMed   Mentions: 2  
    526. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG, CERTIFI Study Group. PMID: 23075178.
      View in: PubMed   Mentions: 390     Fields:    Translation:HumansCTClinical Trials
    527. Infliximab versus ciclosporin in severe ulcerative colitis. Lancet. 2012 Dec 01; 380(9857):1887-8. Levesque BG, Sandborn WJ. PMID: 23063315.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    528. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013 Jan; 108(1):90-8. Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T. PMID: 23044768; PMCID: PMC3538174.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimals
    529. Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013 Mar; 58(3):797-806. Seminerio JL, Loftus EV, Colombel JF, Thapa P, Sandborn WJ. PMID: 23053885.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    530. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology. 2012 Dec; 143(6):1461-9. D'Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M, International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee . PMID: 23000597.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    531. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012 Nov; 107(11):1693-701. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV. PMID: 22945286; PMCID: PMC3572861.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    532. Crohn's disease. Lancet. 2012 Nov 03; 380(9853):1590-605. Baumgart DC, Sandborn WJ. PMID: 22914295.
      View in: PubMed   Mentions: 784     Fields:    Translation:Humans
    533. Ulcerative colitis. Lancet. 2012 Nov 03; 380(9853):1606-19. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. PMID: 22914296.
      View in: PubMed   Mentions: 693     Fields:    Translation:Humans
    534. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16; 367(7):616-24. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W, Study A3921063 Investigators. PMID: 22894574.
      View in: PubMed   Mentions: 299     Fields:    Translation:HumansCTClinical Trials
    535. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):49-54.e1. Samuel S, Bruining DH, Loftus EV, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 22902762; PMCID: PMC10602401.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    536. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep; 107(9):1409-22. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ. PMID: 22890223; PMCID: PMC3438468.
      View in: PubMed   Mentions: 236     Fields:    Translation:Humans
    537. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012 Nov; 143(5):1218-1226.e2. Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. PMID: 22892337.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    538. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1315-1325.e4. Pola S, Patel D, Ramamoorthy S, McLemore E, Fahmy M, Rivera-Nieves J, Chang JT, Evans E, Docherty M, Talamini M, Sandborn WJ. PMID: 22835577; PMCID: PMC4226798.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    539. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Oct; 10(10):1079-87; quiz e85-6. Ordás I, Feagan BG, Sandborn WJ. PMID: 22813440.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    540. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther. 2012 Sep; 36(6):569-74. Mohabbat AB, Sandborn WJ, Loftus EV, Wiesner RH, Bruining DH. PMID: 22779779.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    541. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013 Apr; 7(3):213-21. Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. PMID: 22704916.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    542. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012 Jul; 107(7):1051-63. Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. PMID: 22613901; PMCID: PMC3390465.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    543. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol. 2012 Jul; 107(7):1064-77. D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. PMID: 22565161.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    544. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012 May; 107(5):794-5. Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. PMID: 22552250.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    545. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology. 2012 Aug; 143(2):356-64.e1. Sands BE, Sandborn WJ, Creed TJ, Dayan CM, Dhanda AD, Van Assche GA, Greguš M, Sood A, Choudhuri G, Stempien MJ, Levitt D, Probert CS. PMID: 22549092.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    546. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul; 143(1):62-69.e4. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. PMID: 22504093.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    547. Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1253-9. Samuel S, Bruining DH, Loftus EV, Becker B, Fletcher JG, Mandrekar JN, Zinsmeister AR, Sandborn WJ. PMID: 22503995.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    548. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012 Dec; 18(12):2203-8. Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscandrew M, Hanson KA, Tremaine WJ, Bruining DH, Faubion WA, Pardi DS, Harmsen WS, Zinsmeister AR, Loftus EV. PMID: 22419661.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    549. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012 Apr; 91(4):635-46. Ordás I, Mould DR, Feagan BG, Sandborn WJ. PMID: 22357456.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansAnimals
    550. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012 May; 142(5):1102-1111.e2. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G. PMID: 22326435.
      View in: PubMed   Mentions: 175     Fields:    Translation:Humans
    551. Mucosal healing with infliximab: results from the active ulcerative colitis trials. Gastroenterol Hepatol (N Y). 2012 Feb; 8(2):117-9. Sandborn WJ. PMID: 22485079; PMCID: PMC3317509.
      View in: PubMed   Mentions: 3  
    552. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012 Feb; 6 Suppl 2:S224-34. Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. PMID: 22463929.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    553. IBD in 2011: Advances in IBD management--towards a tailored approach. Nat Rev Gastroenterol Hepatol. 2012 Jan 10; 9(2):70-2. Pineton de Chambrun GP, Sandborn WJ. PMID: 22230905.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    554. Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):400-4. Nguyen DL, Sandborn WJ, Loftus EV, Larson DW, Fletcher JG, Becker B, Mandrekar J, Harmsen WS, Bruining DH. PMID: 22155562.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    555. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 May; 10(5):513-9. Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P. PMID: 22083024.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    556. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb; 142(2):257-65.e1-3. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. PMID: 22062358.
      View in: PubMed   Mentions: 412     Fields:    Translation:HumansCTClinical Trials
    557. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012 Feb; 18(2):349-58. Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. PMID: 22021134.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    558. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut. 2011 Dec; 60(12):1754-63. Ordás I, Feagan BG, Sandborn WJ. PMID: 21997558.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    559. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr; 61(4):535-42. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. PMID: 21997563; PMCID: PMC3292713.
      View in: PubMed   Mentions: 161     Fields:    Translation:Humans
    560. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis. 2012 Jul; 18(7):1240-8. Cipriano LE, Levesque BG, Zaric GS, Loftus EV, Sandborn WJ. PMID: 21928375.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    561. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Dec; 106(12):2070-7; quiz 2078. Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. PMID: 21894226.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    562. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011 Sep; 106(9):1594-602; quiz 1593, 1603. Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. PMID: 21844919.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    563. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011 Oct; 34(7):747-56. Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. PMID: 21848857.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    564. Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease. Inflamm Bowel Dis. 2012 Apr; 18(4):795-6. Levesque BG, Sandborn WJ. PMID: 21739537.
      View in: PubMed   Mentions: 3     Fields:    
    565. Henoch-schönlein purpura in an adult mimicking Crohn's disease and pyoderma gangrenosum. Dig Dis Sci. 2011 Jul; 56(7):2205-6. Samuel S, Loftus EV, Sandborn WJ. PMID: 21249449.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    566. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. PMID: 21723220.
      View in: PubMed   Mentions: 307     Fields:    Translation:Humans
    567. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17. Kamm MA, Hanauer SB, Panaccione R, Colombel JF, Sandborn WJ, Pollack PF, Zhou Q, Robinson AM. PMID: 21645018.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    568. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012 Feb; 61(2):241-7. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF, International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. PMID: 21646246; PMCID: PMC3245899.
      View in: PubMed   Mentions: 98     Fields:    Translation:Humans
    569. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):670-678.e3. Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. PMID: 21642014.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    570. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):679-683.e1. Bruining DH, Loftus EV, Ehman EC, Siddiki HA, Nguyen DL, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS, Sandborn WJ, Fletcher JG. PMID: 21621641.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    571. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb; 18(2):201-11. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Colombel JF, Present D, Sands BE. PMID: 21484965.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    572. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P, American College of Gastroenterology IBD Task Force. PMID: 21472012.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansPHPublic Health
    573. Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. Inflamm Bowel Dis. 2012 Feb; 18(2):275-83. Garrity-Park M, Loftus EV, Sandborn WJ, Smyrk TC. PMID: 21425209.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    574. Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. Inflamm Bowel Dis. 2012 Feb; 18(2):226-35. Kisiel JB, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 21416564.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    575. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011 Apr; 106(4):674-84. Billioud V, Sandborn WJ, Peyrin-Biroulet L. PMID: 21407178.
      View in: PubMed   Mentions: 127     Fields:    Translation:Humans
    576. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. PMID: 21407183.
      View in: PubMed   Mentions: 203     Fields:    Translation:HumansPHPublic Health
    577. Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn's disease in the small bowel. Inflamm Bowel Dis. 2011 Mar; 17(3):778-86. Siddiki H, Fletcher JG, Hara AK, Kofler JM, McCollough CH, Fidler JL, Guimaraes L, Huprich JE, Sandborn WJ, Loftus EV, Mandrekar J, Bruining DH. PMID: 20848546.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    578. Why innovation in inflammatory bowel disease drug development will impact your practice. Clin Gastroenterol Hepatol. 2011 Mar; 9(3):211-3. Sandborn WJ. PMID: 21338946.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    579. Perianal Crohn's disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis. 2012 Jan; 18(1):43-8. Peyrin-Biroulet L, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 21351216; PMCID: PMC3352677.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    580. Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. Inflamm Bowel Dis. 2012 Feb; 18(2):219-25. Bruining DH, Siddiki HA, Fletcher JG, Sandborn WJ, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS, Evans PE, Faubion WA, Hanson KA, Ingle SB, Pardi DS, Schroeder KW, Tremaine WJ, Loftus EV. PMID: 21337477.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    581. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2011 May; 9(5):395-9. Bruining DH, Sandborn WJ. PMID: 21277392.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    582. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011 Mar; 89(3):387-91. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE, Clinical Pharmacogenetics Implementation Consortium. PMID: 21270794; PMCID: PMC3098761.
      View in: PubMed   Mentions: 229     Fields:    Translation:Humans
    583. Reversal of multifocal low- and high-grade dysplasia in patients with an ileoanal pouch. Gastroenterology. 2011 Mar; 140(3):1107-8; author reply 1108-9. Levesque BG, Hanson KA, Sandborn WJ. PMID: 21272556.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    584. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011 Mar; 33(5):541-50. Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. PMID: 21223344.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    585. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. PMID: 21209123.
      View in: PubMed   Mentions: 295     Fields:    Translation:Humans
    586. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011 Jan; 17(1):141-51. Sandborn WJ, Colombel JF, Schreiber S, Plevy SE, Pollack PF, Robinson AM, Chao J, Mulani P. PMID: 20848500.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    587. Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis. 2011 Jan; 17(1):105-11. Thia K, Faubion WA, Loftus EV, Persson T, Persson A, Sandborn WJ. PMID: 20629100.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    588. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011 Feb; 106(2):214-23; quiz 224. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. PMID: 21157441.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    589. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11. Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. PMID: 21104734.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    590. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther. 2011 Jan; 33(2):194-202. Tang T, Targan SR, Li ZS, Xu C, Byers VS, Sandborn WJ. PMID: 21114791.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimals
    591. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011 Jun; 17(6):1415-22. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. PMID: 21560202; PMCID: PMC3116198.
      View in: PubMed   Mentions: 177     Fields:    Translation:Humans
    592. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93. Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ. PMID: 21083671.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    593. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Watermayer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. PMID: 21045814.
      View in: PubMed   Mentions: 144     Fields:    Translation:Humans
    594. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010 Nov; 16(11):1912-21. Swoger JM, Loftus EV, Tremaine WJ, Faubion WA, Pardi DS, Kane SV, Hanson KA, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 20848486.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    595. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 2010 Nov; 59(11):1485-92. Sandborn WJ, Colombel JF, Frankel M, Hommes D, Lowder JN, Mayer L, Plevy S, Stokkers P, Travis S, Van Assche G, Baumgart DC, Targan SR. PMID: 20947884.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    596. The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis. Aliment Pharmacol Ther. 2010 Nov; 32(9):1207-9. Samuel S, Loftus EV, Sandborn WJ. PMID: 21039684.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    597. Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2011 Jun; 17(6):1443-4. Levesque BG, Sandborn WJ. PMID: 21560204.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    598. State-of-the-art: Immunosuppression and biologic therapy. Dig Dis. 2010; 28(3):536-42. Sandborn WJ. PMID: 20926883.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    599. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011 Jun; 17(6):1257-64. Thia KT, Loftus EV, Pardi DS, Kane SV, Faubion WA, Tremaine WJ, Schroeder KW, Harmsen SW, Zinsmeister AR, Sandborn WJ. PMID: 20878712.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    600. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg. 2010 Dec; 14(12):1859-65; discussion 1865-6. Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ, Loftus EV, Larson DW. PMID: 20872084.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    601. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis. 2011 Jan; 17(1):471-8. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. PMID: 20725943.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    602. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010 Oct; 139(4):1147-55. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV. PMID: 20637205; PMCID: PMC2950117.
      View in: PubMed   Mentions: 231     Fields:    Translation:Humans
    603. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010 Jun 16; (6):CD001176. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. PMID: 20556748.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    604. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. PMID: 20491747.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    605. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):688-695.e2. Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. PMID: 20451663.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    606. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15; 362(15):1383-95. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P, SONIC Study Group. PMID: 20393175.
      View in: PubMed   Mentions: 919     Fields:    Translation:Humans
    607. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010 May; 105(5):1142-9. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. PMID: 20389296.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    608. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1. Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR, PRECiSE 4 Study Investigators. PMID: 20363366.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    609. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9. Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. PMID: 19714757.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    610. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Jun; 31(12):1296-309. Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D'Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF. PMID: 20298496.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    611. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010 Jul; 105(7):1574-82. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ, PRECiSE 2 Study Investigators. PMID: 20234346.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    612. How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease. Dig Dis. 2009; 27 Suppl 1:80-4. Sandborn WJ. PMID: 20203501.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    613. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010 Jul; 105(7):1610-9. Garrity-Park MM, Loftus EV, Sandborn WJ, Bryant SC, Smyrk TC. PMID: 20160714.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    614. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May; 105(5):1133-9. Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. PMID: 20145610; PMCID: PMC6937708.
      View in: PubMed   Mentions: 145     Fields:    Translation:Humans
    615. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut. 2010 Feb; 59(2):141-7. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. PMID: 20176633.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    616. Assessment of appropriateness of indications for CT enterography in younger patients. Inflamm Bowel Dis. 2010 Feb; 16(2):226-32. Guimarães LS, Fidler JL, Fletcher JG, Bruining DH, Huprich JE, Siddiki H, Sandborn WJ, Loftus EV, Pardi DS, McCollough CH. PMID: 19637359.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    617. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9. Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ, Precise 3 Study Investigators. PMID: 20117244.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    618. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010 Apr; 8(4):357-63. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. PMID: 20096379.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansAnimals
    619. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010 Apr; 138(4):1286-96, 1296.e1-3. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. PMID: 20064514.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    620. Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease. Arch Surg. 2010 Jan; 145(1):42-7. Malireddy K, Larson DW, Sandborn WJ, Loftus EV, Faubion WA, Pardi DS, Qin R, Gullerud RE, Cima RR, Wolff B, Dozois EJ. PMID: 20083753.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    621. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010 Jan; 16(1):15-22. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Kostanjsek N, Kamm MA, Hibi T, Lémann M, Stucki G, Colombel JF. PMID: 19610077.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    622. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010 Feb; 105(2):289-97. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. PMID: 19861953.
      View in: PubMed   Mentions: 314     Fields:    Translation:Humans
    623. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009 Oct; 15(10):1599-604. D'Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Schölmerich J, Hanauer S, Sandborn WJ, IOIBD Membership. PMID: 19653291.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    624. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. PMID: 19766640.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    625. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009 Sep; 15(9):1308-19. Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. PMID: 19434735.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    626. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7. Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn WJ. PMID: 19408340.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    627. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009 Sep; 15(9):1326-30. Ravi K, Chari ST, Vege SS, Sandborn WJ, Smyrk TC, Loftus EV. PMID: 19235915.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    628. Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther. 2009 Nov 01; 30(9):930-6. Manabe N, Cremonini F, Camilleri M, Sandborn WJ, Burton DD. PMID: 19678812; PMCID: PMC2862903.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    629. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol. 2009 Nov; 104(11):2768-73. Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. PMID: 19672253.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    630. Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride? Am J Gastroenterol. 2009 Aug; 104(8):2097-9. Velayos FS, Sandborn WJ. PMID: 19661939.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    631. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. PMID: 19596014.
      View in: PubMed   Mentions: 138     Fields:    Translation:Humans
    632. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol. 2009 Jul; 193(1):113-21. Siddiki HA, Fidler JL, Fletcher JG, Burton SS, Huprich JE, Hough DM, Johnson CD, Bruining DH, Loftus EV, Sandborn WJ, Pardi DS, Mandrekar JN. PMID: 19542402.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    633. CT enterography and fistulizing Crohn's disease: clinical benefit and radiographic findings. Abdom Imaging. 2009 Jul; 34(4):467-75. Booya F, Akram S, Fletcher JG, Huprich JE, Johnson CD, Fidler JL, Barlow JM, Solem CA, Sandborn WJ, Loftus EV. PMID: 18551336.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    634. MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2009 Jul; 5(7):494-500. Hanauer SB, Lichtenstein GR, Kamm MA, Sandborn WJ, Lees KH, Barrett K, Karlstadt RG, Diebold R, Joseph RE. PMID: 37967434; PMCID: PMC2886429.
      View in: PubMed   Mentions:
    635. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009 Oct; 104(10):2524-33. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. PMID: 19532125.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    636. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36. Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W, Crohn's Disease Photopheresis Study Group. PMID: 19130617.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    637. Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease. Clin Gastroenterol Hepatol. 2009 Oct; 7(10):1139. Peyrin-Biroulet L, Colombel JF, Sandborn WJ. PMID: 19465159.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    638. Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study. Inflamm Bowel Dis. 2009 May; 15(5):772-7. Hanson KA, Loftus EV, Harmsen WS, Diehl NN, Zinsmeister AR, Sandborn WJ. PMID: 19107782.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    639. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009 Aug; 30(3):210-26. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ. PMID: 19392858.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    640. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009 May; 104(5):1170-9. Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. PMID: 19352339.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    641. Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflamm Bowel Dis. 2009 Apr; 15(4):566-75. Loftus EV, Friedman HS, Delgado DJ, Sandborn WJ. PMID: 19143006.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    642. MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut. 2009 Sep; 58(9):1226-33. Garrity-Park MM, Loftus EV, Sandborn WJ, Bryant SC, Smyrk TC. PMID: 19251712.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    643. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol. 2009 Apr; 104(4):868-76. Baumgart DC, Lowder JN, Targan SR, Sandborn WJ, Frankel MB. PMID: 19240707.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    644. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009 Jul; 58(7):940-8. Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. PMID: 19201775; PMCID: PMC2689393.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    645. Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb; 104(2):465-83; quiz 464, 484. Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. PMID: 19174807.
      View in: PubMed   Mentions: 282     Fields:    Translation:Humans
    646. The future of inflammatory bowel disease care. Rev Gastroenterol Disord. 2009; 9(3):E69-77. Sandborn WJ. PMID: 19898267.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    647. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009 Jan; 15(1):1-8. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. PMID: 18671232.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    648. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009 Jan; 15(1):17-24. Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. PMID: 18668682.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    649. Relationships between C-reactive protein concentration and genotype in healthy volunteers. Clin Chem Lab Med. 2009; 47(1):20-5. Jones J, Chen LS, Baudhuin L, Peterson S, Harmsen WS, Zinsmeister AR, McConnell J, Sandborn WJ. PMID: 19072030.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    650. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm Bowel Dis. 2008 Dec; 14(12):1701-6. Bruining DH, Siddiki HA, Fletcher JG, Tremaine WJ, Sandborn WJ, Loftus EV. PMID: 18623171.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    651. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008 Dec; 103(12):3167-82. Thia KT, Loftus EV, Sandborn WJ, Yang SK. PMID: 19086963.
      View in: PubMed   Mentions: 234     Fields:    Translation:Humans
    652. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31. Thia KT, Sandborn WJ, Lewis JD, Loftus EV, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE. PMID: 18786111.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    653. AGA Institute Future Trends Committee report: the future of gastroenterology training programs in the United States. Gastroenterology. 2008 Nov; 135(5):1764-89.e2. Wang TC, Cominelli F, Fleischer DE, Gordon JM, Glickman RM, Limsui D, McQuaid KR, Montrose M, Pasricha PJ, Powell DW, Rowe WA, Sandborn WJ, Todisco A. PMID: 19009690.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    654. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008 Nov; 135(5):1442-7. Sandborn WJ. PMID: 18848556.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    655. Is there a role for infliximab in the treatment of severe ulcerative colitis?: the American experience. Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S232-3. Sandborn WJ. PMID: 18816658.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    656. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008 Nov; 6(11):1218-24. Jones J, Loftus EV, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn WJ. PMID: 18799360.
      View in: PubMed   Mentions: 123     Fields:    Translation:Humans
    657. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008 Sep 15; 28(6):674-88. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. PMID: 18532990.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    658. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov; 135(5):1493-9. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. PMID: 18848553.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCTClinical Trials
    659. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008 Oct; 135(4):1130-41. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P, Ustekinumab Crohn's Disease Study Group. PMID: 18706417.
      View in: PubMed   Mentions: 239     Fields:    Translation:Humans
    660. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet. 2008 Jul 05; 372(9632):67-81. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. PMID: 18603161.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    661. Certolizumab Pegol for Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2008 Jul; 4(7):467-8. Sandborn WJ. PMID: 21960919; PMCID: PMC3096126.
      View in: PubMed   Mentions: 2  
    662. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2008 Aug; 103(8):2015-22. Peloquin JM, Pardi DS, Sandborn WJ, Fletcher JG, McCollough CH, Schueler BA, Kofler JA, Enders FT, Achenbach SJ, Loftus EV. PMID: 18564113; PMCID: PMC2831296.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    663. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008 Jul; 103(7):1737-45. Loftus EV, Delgado DJ, Friedman HS, Sandborn WJ. PMID: 18564126.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    664. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008 Aug; 68(2):255-66. Solem CA, Loftus EV, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 18513722.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCTClinical Trials
    665. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008 Jun; 6(6):644-53. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. PMID: 18550004.
      View in: PubMed   Mentions: 144     Fields:    Translation:Humans
    666. Indeterminate colitis: a review of the concept--what's in a name? Inflamm Bowel Dis. 2008 Jun; 14(6):850-7. Geboes K, Colombel JF, Greenstein A, Jewell DP, Sandborn WJ, Vatn MH, Warren B, Riddell RH, Pathology Task Force of the International Organization of Inflammatory Bowel Diseases. PMID: 18213696.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    667. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug; 135(2):400-9. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S, Adacolumn Study Group. PMID: 18602921.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    668. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA. 2008 Apr 09; 299(14):1690-7. Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, Cohen A, Dallaire C, Ponich TP, McDonald JW, Hébuterne X, Paré P, Klvana P, Niv Y, Ardizzone S, Alexeeva O, Rostom A, Kiudelis G, Spleiss J, Gilgen D, Vandervoort MK, Wong CJ, Zou GY, Donner A, Rutgeerts P. PMID: 18398081.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansPHPublic Health
    669. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol. 2008 Apr; 42(4):338-44. Sandborn WJ. PMID: 18277908.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    670. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008 Jun 01; 27(11):1094-102. Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE. PMID: 18363894.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    671. Initial combination therapy in early Crohn's disease. Lancet. 2008 Feb 23; 371(9613):635-636. Sandborn WJ. PMID: 18295013.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    672. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008 Jul; 57(7):893-902. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. PMID: 18272546; PMCID: PMC2564831.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    673. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2008 Feb; 103(2):407-15. Garrity-Park MM, Loftus EV, Bryant SC, Sandborn WJ, Smyrk TC. PMID: 18289203.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    674. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008 Apr; 134(4):929-36. Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. PMID: 18294633.
      View in: PubMed   Mentions: 320     Fields:    Translation:Humans
    675. Mucosal healing in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(4):271-2. Sandborn WJ. PMID: 19107101.
      View in: PubMed   Mentions:    Fields:    
    676. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol. 2007 Dec; 102(12):2737-46. Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. PMID: 18042106.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    677. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N. PMID: 18080055; PMCID: PMC2658575.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    678. Positioning biologic therapy for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep. 2007 Dec; 9(6):521-7. Velayos FS, Sandborn WJ. PMID: 18377806.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    679. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007 Oct; 13(10):1250-5. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D, Sandborn WJ, Crohn's and Colitis Foundation of America Clinical Alliance. PMID: 17567869.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    680. Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis. 2007 Oct; 13(10):1266-70. Cima RR, Anderson KJ, Larson DW, Dozois EJ, Hassan I, Sandborn WJ, Loftus EV, Pemberton JH. PMID: 17567877.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    681. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007 Oct 01; 26(7):987-1003. Sandborn WJ, Feagan BG, Lichtenstein GR. PMID: 17877506.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    682. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007 Sep; 13(9):1135-40. Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, Radford-Smith G, Xu S, Eisenberg D, Olson A, Colombel JF. PMID: 17476675.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    683. Treatment of Crohn's disease with certolizumab pegol. Expert Rev Clin Immunol. 2007 Sep; 3(5):683-94. Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. PMID: 20477019.
      View in: PubMed   Mentions:    Fields:    
    684. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007 Nov; 133(5):1414-22. Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. PMID: 17920064.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    685. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007 Oct; 133(4):1106-12. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. PMID: 17764676.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansPHPublic Health
    686. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):228-38. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators. PMID: 17634458.
      View in: PubMed   Mentions: 290     Fields:    Translation:Humans
    687. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators. PMID: 17634459.
      View in: PubMed   Mentions: 256     Fields:    Translation:Humans
    688. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007 Jul 15; 26(2):205-15. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. PMID: 17593066.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    689. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul; 133(1):312-39. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. PMID: 17631151.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    690. Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease. Aliment Pharmacol Ther. 2007 Jun 15; 25(12):1435-41. Tremaine WJ, Timmons LJ, Loftus EV, Pardi DS, Sandborn WJ, Harmsen WS, Thapa P, Zinsmeister AR. PMID: 17539983.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    691. A moveable feast. Clin Gastroenterol Hepatol. 2007 Jun; 5(6):646-7. Camilleri M, Sandborn WJ, Kolars JC, Murray JA, Poterucha JJ, Roberts L, Sinicrope FA, Wang KK. PMID: 17544990.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    692. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12; 369(9573):1641-57. Baumgart DC, Sandborn WJ. PMID: 17499606.
      View in: PubMed   Mentions: 636     Fields:    Translation:Humans
    693. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007 May; 204(5):956-62; discussion 962-3. Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV, Sandborn WJ, Wolff BG, Pemberton JH. PMID: 17481518.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    694. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. PMID: 17470824.
      View in: PubMed   Mentions: 258     Fields:    Translation:Humans
    695. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007 May; 132(5):1672-83. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. PMID: 17484865.
      View in: PubMed   Mentions: 190     Fields:    Translation:Humans
    696. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007 Mar; 13(3):254-61. Loftus CG, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Sandborn WJ. PMID: 17206702.
      View in: PubMed   Mentions: 214     Fields:    Translation:Humans
    697. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. PMID: 17324131.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    698. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. PMID: 17299059; PMCID: PMC2701613.
      View in: PubMed   Mentions: 277     Fields:    Translation:Humans
    699. European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut. 2007 Feb; 56(2):161-3. Hanauer SB, Sandborn WJ. PMID: 17303600; PMCID: PMC1856750.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    700. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007 Feb; 13(2):175-81. Limsui D, Pardi DS, Camilleri M, Loftus EV, Kammer PP, Tremaine WJ, Sandborn WJ. PMID: 17206699.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    701. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007 Apr; 102(4):829-36. Jess T, Loftus EV, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P, Sandborn WJ. PMID: 17222314.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansPHPublic Health
    702. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007 Feb 01; 25(3):247-55. Desai D, Faubion WA, Sandborn WJ. PMID: 17217454.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    703. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007 Jan; 5(1):95-102. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. PMID: 17234558.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCTClinical Trials
    704. Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2. Hanauer SB, Sandborn WJ. PMID: 17392632.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    705. Clinical perspectives in Crohn's disease: now and in the future. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 2:S1-2. Sandborn WJ. PMID: 17392634.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    706. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord. 2007; 7 Suppl 2:S23-35. Sandborn WJ. PMID: 17392636.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    707. A new treatment option for ulcerative colitis. Rev Gastroenterol Disord. 2007; 7(2):106-7. Sandborn WJ. PMID: 17597673.
      View in: PubMed   Mentions:    Fields:    
    708. Step-up versus top-down therapy in the treatment of ulcerative colitis. Gastroenterol Hepatol (N Y). 2007 Jan; 3(1):16-7. Sandborn WJ. PMID: 21960772; PMCID: PMC3096114.
      View in: PubMed   Mentions: 10  
    709. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. PMID: 17258735.
      View in: PubMed   Mentions: 335     Fields:    Translation:Humans
    710. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2006 Dec; 12(12):1093-100. Tung J, Loftus EV, Freese DK, El-Youssef M, Zinsmeister AR, Melton LJ, Harmsen WS, Sandborn WJ, Faubion WA. PMID: 17119382.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    711. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007 Apr; 56(4):504-8. Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ, Sandborn WJ. PMID: 17135309; PMCID: PMC1856874.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    712. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. PMID: 17241859.
      View in: PubMed   Mentions: 597     Fields:    Translation:HumansCTClinical Trials
    713. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):66-75; quiz 432-3. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. PMID: 17241860.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCTClinical Trials
    714. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology. 2006 Dec; 241(3):787-95. Booya F, Fletcher JG, Huprich JE, Barlow JM, Johnson CD, Fidler JL, Solem CA, Sandborn WJ, Loftus EV, Harmsen WS. PMID: 17032911.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    715. Microscopic colitis is not associated with cholecystectomy or appendectomy. Inflamm Bowel Dis. 2006 Aug; 12(8):708-11. Laing AW, Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ, Sandborn WJ. PMID: 16917225.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    716. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006 Aug; 12(8):669-76. Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ, Munkholm P, Sandborn WJ. PMID: 16917220.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    717. Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice. J Clin Gastroenterol. 2006 Aug; 40(7):587-91. Sands BE, Kilgore KM, Bloomfeld RS, Sandborn WJ. PMID: 16917398.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    718. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9. Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. PMID: 16825929.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    719. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):888-93. Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M, Onercept Study Group. PMID: 16797249.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    720. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology. 2006 Jun; 130(7):1941-9. Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. PMID: 16762617.
      View in: PubMed   Mentions: 99     Fields:    Translation:Humans
    721. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May; 4(5):621-30. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. PMID: 16678077.
      View in: PubMed   Mentions: 229     Fields:    Translation:Humans
    722. CLASSIC-I study the efficacy of adalimumab. Gastroenterology. 2006 May; 130(6):1929-30. Schreiber S, Sandborn WJ. PMID: 16697761.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    723. What's new: innovative concepts in inflammatory bowel disease. Colorectal Dis. 2006 May; 8 Suppl 1:3-9. Sandborn WJ. PMID: 16594957.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    724. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. PMID: 16606351.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    725. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut. 2006 Nov; 55(11):1561-7. Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG. PMID: 16648154; PMCID: PMC1860143.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    726. Systematic review: the management of pouchitis. Aliment Pharmacol Ther. 2006 Apr 15; 23(8):1087-96. Pardi DS, Sandborn WJ. PMID: 16611268.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    727. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 2006 Nov; 55(11):1568-74. Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS. PMID: 16603634; PMCID: PMC1860086.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    728. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006 Apr; 130(4):1039-46. Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ, Munkholm P, Sandborn WJ. PMID: 16618397.
      View in: PubMed   Mentions: 128     Fields:    Translation:Humans
    729. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006 Mar 01; 23(5):617-28. Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A. PMID: 16480401.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    730. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006 Feb; 4(2):203-11. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ. PMID: 16469681.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    731. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. PMID: 16472588.
      View in: PubMed   Mentions: 452     Fields:    Translation:Humans
    732. Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology. 2006 Feb; 238(2):505-16. Bodily KD, Fletcher JG, Solem CA, Johnson CD, Fidler JL, Barlow JM, Bruesewitz MR, McCollough CH, Sandborn WJ, Loftus EV, Harmsen WS, Crownhart BS. PMID: 16436815.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    733. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006 Sep; 55(9):1248-54. Jess T, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Munkholm P, Sandborn WJ. PMID: 16423890; PMCID: PMC1860022.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    734. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006 Jan; 12(1):29-32. Chopra A, Pardi DS, Loftus EV, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ. PMID: 16374255.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    735. Best of DDW 2006. Rev Gastroenterol Disord. 2006; 6(3):153-89. Hanauer SB, Sandborn WJ, Vakil N, Katz PO, Talley NJ, Rex DK, Hawes RH, Guda NM, Freeman ML, Keeffe EB, Balart LA. PMID: 16957658.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    736. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord. 2006; 6(2):97-105. Sandborn WJ. PMID: 16699478.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    737. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis. 2006 Jan; 12 Suppl 1:S15-21. Sandborn WJ. PMID: 16378006.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    738. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 08; 353(23):2462-76. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. PMID: 16339095.
      View in: PubMed   Mentions: 1157     Fields:    Translation:Humans
    739. Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep. 2005 Dec; 7(6):485-91. Egan LJ, Sandborn WJ. PMID: 16313879.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    740. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005 Dec; 11(12):1080-4. Moolsintong P, Loftus EV, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ. PMID: 16306770.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    741. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P, International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group, Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. PMID: 16267322.
      View in: PubMed   Mentions: 252     Fields:    Translation:HumansCellsCTClinical Trials
    742. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S22-8. Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. PMID: 16254479.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    743. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S3-12. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. PMID: 16254481.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimals
    744. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. PMID: 16279903.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    745. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005 Oct; 100(10):2239-47. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. PMID: 16181376.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    746. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005 Aug; 11(8):707-12. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 16043984.
      View in: PubMed   Mentions: 178     Fields:    Translation:Humans
    747. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug; 100(8):1780-7. Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. PMID: 16086715.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    748. Total laparoscopic proctocolectomy with Brooke ileostomy: a novel incisionless surgical treatment for patients with ulcerative colitis. Surg Endosc. 2005 Sep; 19(9):1284-7. Larson DW, Dozois E, Sandborn WJ, Cima R. PMID: 16132322.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    749. Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis. 2005 May; 11(5):428-34. Toruner M, Harewood GC, Loftus EV, Sandborn WJ, Tremaine WJ, Faubion WA, Schroeder KW, Egan LJ. PMID: 15867581.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    750. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. PMID: 15771759.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    751. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut. 2005 Mar; 54(3):321-2. Pardi DS, Sandborn WJ. PMID: 15710974; PMCID: PMC1774419.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    752. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84. Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. PMID: 15709987.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    753. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):363-71. Hanauer S, Sandborn WJ, Persson A, Persson T. PMID: 15709986.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    754. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005 Jan; 54(1):91-6. Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ. PMID: 15591511; PMCID: PMC1774346.
      View in: PubMed   Mentions: 214     Fields:    Translation:Humans
    755. Inflammatory bowel disease: a new combination therapy for pouchitis. Rev Gastroenterol Disord. 2005; 5(2):110. Sandborn WJ. PMID: 15976743.
      View in: PubMed   Mentions:    Fields:    
    756. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord. 2005; 5(1):10-8. Sandborn WJ. PMID: 15741928.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    757. Clinical management of pouchitis. Gastroenterology. 2004 Dec; 127(6):1809-14. Sandborn WJ, Pardi DS. PMID: 15578518.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    758. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004 Nov 11; 351(20):2069-79. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W, Anti-IL-12 Crohn's Disease Study Group. PMID: 15537905.
      View in: PubMed   Mentions: 234     Fields:    Translation:HumansCellsCTClinical Trials
    759. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9. Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. PMID: 15447761.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    760. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004 Oct; 53(10):1485-93. Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. PMID: 15361500; PMCID: PMC1774244.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    761. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005 Feb; 312(2):537-45. Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, McKean DJ, Lipsky JJ, Sandborn WJ, Egan LJ. PMID: 15388785.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    762. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology. 2004 Sep; 127(3):990-3. Sandborn WJ, Feagan BG. PMID: 15362055.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    763. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004 Sep; 10(5):657-60. Velayos FS, Sandborn WJ. PMID: 15472531.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    764. Biologics in inflammatory bowel disease: how much progress have we made? Gut. 2004 Sep; 53(9):1366-73. Sandborn WJ, Faubion WA. PMID: 15306602; PMCID: PMC1774209.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    765. Medical therapy of Crohn disease. Curr Opin Gastroenterol. 2004 Jul; 20(4):351-9. Panaccione R, Sandborn WJ. PMID: 15703664.
      View in: PubMed   Mentions: 1     Fields:    
    766. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut. 2004 Jun; 53(6):780-2. Sandborn WJ, Loftus EV. PMID: 15138201; PMCID: PMC1774089.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    767. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2004 Jun; 33(2):141-69, vii. Loftus CG, Egan LJ, Sandborn WJ. PMID: 15177532.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    768. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004 May 15; 19(10):1089-98. Sandborn WJ, Hanauer SB, Buch A. PMID: 15142198.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    769. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004 May; 10(3):207-14. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 15290913.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    770. Advances in the treatment of Crohn's disease. Gastroenterology. 2004 May; 126(6):1574-81. Egan LJ, Sandborn WJ. PMID: 15168368.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    771. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004 May; 99(5):878-83. Colombel JF, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. PMID: 15128354.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    772. Mid pouch strictureplasty for Crohn's disease after ileal pouch-anal anastomosis: an alternative to pouch excision. Dis Colon Rectum. 2004 May; 47(5):782-6. Matzke GM, Kang AS, Dozois EJ, Sandborn WJ. PMID: 15037928.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    773. Pharmacogenomics and IBD: TPMT and thiopurines. Inflamm Bowel Dis. 2004 Feb; 10 Suppl 1:S35-7. Sandborn WJ. PMID: 15168829.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    774. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004 Jan; 10(1):28-31. Thomas CW, Weinshenker BG, Sandborn WJ. PMID: 15058523.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    775. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S25-33. Sandborn WJ. PMID: 15583528.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    776. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004 Jan; 126(1):19-31. Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. PMID: 14699483.
      View in: PubMed   Mentions: 186     Fields:    Translation:Humans
    777. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004 Jan; 99(1):97-101. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 14687149.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    778. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord. 2004; 4(4):167-74. Sandborn WJ. PMID: 15580151.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    779. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep. 2003 Dec; 5(6):501-5. Sandborn WJ. PMID: 14602060.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    780. Evidence-based treatment algorithm for mild to moderate Crohn's disease. Am J Gastroenterol. 2003 Dec; 98(12 Suppl):S1-5. Sandborn WJ. PMID: 14697912.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    781. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov; 125(5):1508-30. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice Committee. PMID: 14598268.
      View in: PubMed   Mentions: 147     Fields:    Translation:Humans
    782. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003 Nov; 1(6):465-73. Loftus EV, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ. PMID: 15017646.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    783. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol. 2003 Nov; 98(11):2372-82. Sandborn WJ, Yednock TA. PMID: 14638336.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    784. Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003 Oct; 98(10):2239-44. Colombel JF, Ricart E, Loftus EV, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. PMID: 14572574.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    785. Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. Radiology. 2003 Oct; 229(1):275-81. Wold PB, Fletcher JG, Johnson CD, Sandborn WJ. PMID: 12944602.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    786. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003 Aug; 125(2):380-8. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. PMID: 12891539.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    787. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 2003 Aug 01; 18(3):263-77. Sandborn WJ, Feagan BG. PMID: 12895211.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    788. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis. 2003 Jul; 9(4):237-45. Thomas CW, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. PMID: 12902847.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    789. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 01; 17(11):1355-64. Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV, Graeme-Cook F, Odenheimer DJ, Hanauer SB. PMID: 12786629.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    790. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. PMID: 12818275.
      View in: PubMed   Mentions: 111     Fields:    Translation:Humans
    791. Challenges in IBD Research: updating the scientific agendas. Inflamm Bowel Dis. 2003 May; 9(3):137-53. Elson CO, Sartor RB, Targan SR, Sandborn WJ. PMID: 12792219.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    792. Diagnosis and management of pouchitis. Gastroenterology. 2003 May; 124(6):1636-50. Mahadevan U, Sandborn WJ. PMID: 12761722.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    793. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology. 2003 Apr; 124(4):1140-5. Sandborn WJ. PMID: 12671907.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    794. Cyclosporin for refractory ulcerative colitis. Gut. 2003 Feb; 52(2):172-3. Loftus CG, Loftus EV, Sandborn WJ. PMID: 12524395; PMCID: PMC1774959.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    795. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):105-17. Sandborn WJ. PMID: 12617886.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    796. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003 Jan; 17(1):29-42. Sandborn WJ, Hanauer SB. PMID: 12492730.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    797. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol. 2002 Dec; 97(12):2939-41. Sandborn WJ. PMID: 12492172.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    798. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec; 97(12):2962-72. Sandborn WJ, Hanauer SB. PMID: 12492177.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    799. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002 Sep; 8(5):311-6. Mahadevan U, Loftus EV, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. PMID: 12479645.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    800. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002 Aug; 123(2):468-75. Loftus EV, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ. PMID: 12145800.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    801. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol. 2002 Jul; 97(7):1763-8. Ricart E, Taylor WR, Loftus EV, O'Kane D, Weinshilboum RM, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 12135032.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    802. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002 May; 122(6):1592-608. Sandborn WJ, Targan SR. PMID: 12016425.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    803. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr; 122(4):875-80. Schwartz DA, Loftus EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 11910338.
      View in: PubMed   Mentions: 252     Fields:    Translation:Humans
    804. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002 Apr; 97(4):910-4. Mahadevan U, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 12008668.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    805. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol. 2002 Apr; 97(4):922-7. Ullman TA, Loftus EV, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. PMID: 12008669.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    806. Microscopic colitis: a review. Am J Gastroenterol. 2002 Apr; 97(4):794-802. Pardi DS, Smyrk TC, Tremaine WJ, Sandborn WJ. PMID: 12003412.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    807. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):1-20. Loftus EV, Sandborn WJ. PMID: 12122726.
      View in: PubMed   Mentions: 138     Fields:    Translation:Humans
    808. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? Rev Gastroenterol Disord. 2002; 2 Suppl 2:S9-15. Feagan BG, Sandborn WJ. PMID: 12478239.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    809. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002 Jan; 16(1):51-60. Loftus EV, Schoenfeld P, Sandborn WJ. PMID: 11856078.
      View in: PubMed   Mentions: 133     Fields:    Translation:HumansPHPublic Health
    810. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002 Jan; 122(1):72-7. Dayharsh GA, Loftus EV, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ. PMID: 11781282.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    811. Evolving medical therapies for Crohn's disease. Curr Gastroenterol Rep. 2001 Dec; 3(6):471-6. Mahadevan U, Sandborn WJ. PMID: 11696284.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    812. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med. 2001 Nov 20; 135(10):906-18. Schwartz DA, Pemberton JH, Sandborn WJ. PMID: 11712881.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    813. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001 Nov; 49(5):665-70. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. PMID: 11600469; PMCID: PMC1728511.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    814. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001 Nov; 49(5):656-64. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, Tremaine WJ, Lipsky JJ, Weinshilboum RM, Sandborn WJ. PMID: 11600468; PMCID: PMC1728490.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    815. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J Chromatogr B Biomed Sci Appl. 2001 Jun 05; 757(1):1-9. Pike MG, Franklin CL, Mays DC, Lipsky JJ, Lowry PW, Sandborn WJ. PMID: 11419732.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    816. Increased eosinophil infiltration and degranulation in colonic tissue from patients with collagenous colitis. Am J Gastroenterol. 2001 May; 96(5):1522-8. Levy AM, Yamazaki K, Van Keulen VP, Burgart LJ, Sandborn WJ, Phillips SF, Kephart GM, Gleich GJ, Leiferman KM. PMID: 11374693.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    817. Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001 May; 48(5):591-2. Sandborn WJ. PMID: 11302950; PMCID: PMC1728293.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    818. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May; 120(6):1330-8. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR, CDP571 Crohn's Disease Study Group. PMID: 11313302.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    819. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology. 2001 May; 120(6):1483-4. Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 11313319.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    820. Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther. 2001 May; 15(5):653-63. Coulie B, Camilleri M, Bharucha AE, Sandborn WJ, Burton D. PMID: 11328259.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    821. Management of Crohn's disease in adults. Am J Gastroenterol. 2001 Mar; 96(3):635-43. Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology. PMID: 11280528.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    822. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001 Mar; 96(3):722-9. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 11280541.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    823. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis. 2001 Feb; 7(1):38-42. Mahadevan U, Sandborn WJ. PMID: 11233659.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    824. Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol. 2000 Dec; 95(12):3463-8. Mahadevan U, Tremaine WJ, Johnson T, Pike MG, Mays DC, Lipsky JJ, Sandborn WJ. PMID: 11151878.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    825. Clinical pharmacology of inflammatory bowel disease therapies. Curr Gastroenterol Rep. 2000 Dec; 2(6):440-5. Sandborn WJ, Faubion WA. PMID: 11079044.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    826. Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: a case study of five patients with treatment-resistant inflammatory bowel disease. Inflamm Bowel Dis. 2000 Nov; 6(4):286-9. Egan LJ, Tremaine WJ, Mays DC, Lipsky JJ, Sandborn WJ. PMID: 11149561.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    827. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000 Oct; 95(10):2831-7. Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. PMID: 11051356.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    828. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000 Sep; 95(9):2308-12. Loftus EV, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 11007233.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    829. Steroid-dependent Crohn's disease. Can J Gastroenterol. 2000 Sep; 14 Suppl C:17C-22C. Sandborn WJ. PMID: 11023556.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    830. Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis. 2000 Aug; 6(3):157-64. Bulois P, Tremaine WJ, Maunoury V, Gambiez L, Hafraoui S, Leteurtre L, Cortot A, Sandborn WJ, Colombel JF, Desreumaux P. PMID: 10961587.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    831. Therapy for Crohn disease. Curr Opin Gastroenterol. 2000 Jul; 16(4):318-23. Sandborn WJ. PMID: 17031095.
      View in: PubMed   Mentions: 2     Fields:    
    832. Early measles virus infection is associated with the development of inflammatory bowel disease. Am J Gastroenterol. 2000 Jun; 95(6):1480-5. Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Poland GA, Harmsen WS, Zinsmeister AR, Melton LJ. PMID: 10894583.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    833. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad. Gastroenterology. 2000 Mar; 118(3):630-1. Faubion WA, Sandborn WJ. PMID: 10702217.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    834. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000 Mar; 46(3):336-43. Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. PMID: 10673294; PMCID: PMC1727835.
      View in: PubMed   Mentions: 138     Fields:    Translation:Humans
    835. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000 Feb; 6(1):8-15. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. PMID: 10701144.
      View in: PubMed   Mentions: 281     Fields:    Translation:Humans
    836. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000; (2):CD000545. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. PMID: 10796557.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    837. Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst Rev. 2000; (2):CD001176. Sandborn W, McLeod R, Jewell D. PMID: 10796613.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    838. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 1999 Dec; 13(12):1597-604. Egan LJ, Sandborn WJ, Tremaine WJ, Leighton JA, Mays DC, Pike MG, Zinsmeister AR, Lipsky JJ. PMID: 10594394.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    839. Infliximab for the treatment of fistulas in patients with Crohn'S disease. Gastroenterology. 1999 Nov; 117(5):1247-8. Ricart E, Sandborn WJ. PMID: 10535892.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCTClinical Trials
    840. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999 Nov; 5(4):239-45. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. PMID: 10579116.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    841. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999 Sep 10; 274(37):26448-53. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, Lipsky JJ, McKean DJ. PMID: 10473604.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    842. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999 Sep; 117(3):527-35. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH. PMID: 10464128.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCellsCTClinical Trials
    843. Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis. 1999 Aug; 5(3):167-73. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. PMID: 10453372.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    844. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology. 1999 Aug; 117(2):429-32. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 10419926.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    845. Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. Inflamm Bowel Dis. 1999 Aug; 5(3):174-81. Louvet B, Buisine MP, Desreumaux P, Tremaine WJ, Aubert JP, Porchet N, Capron M, Cortot A, Colombel JF, Sandborn WJ. PMID: 10453373.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    846. Mycophenolate mofetil for Crohn's disease? Lancet. 1999 Jul 03; 354(9172):3-4. Lowry PW, Sandborn WJ, Lipsky JJ. PMID: 10406354.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    847. The appendix in ulcerative colitis: a not so innocent bystander. Gastroenterology. 1999 Jul; 117(1):272-3. Panaccione R, Sandborn WJ. PMID: 10381940.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    848. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999 Jul; 117(1):49-57. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. PMID: 10381909.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    849. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology. 1999 Jun; 116(6):1505-6. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. PMID: 10391741.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    850. Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis. 1999 May; 5(2):98-103. Harewood GC, Loftus EV, Tefferi A, Tremaine WJ, Sandborn WJ. PMID: 10338378.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    851. Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. Inflamm Bowel Dis. 1999 May; 5(2):104-6. Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Poland GA, Melton LJ. PMID: 10338379.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    852. A comparison of budesonide and mesalamine for active Crohn's disease. Gastroenterology. 1999 May; 116(5):1263. Lowry PW, Sandborn WJ. PMID: 10220523.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    853. Practice guidelines for inflammatory bowel disease: an instrument for assessment. Mayo Clin Proc. 1999 May; 74(5):495-501. Tremaine WJ, Sandborn WJ. PMID: 10319083.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    854. Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol. 1999 May; 94(5):1161-71. Sandborn WJ. PMID: 10235187.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    855. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33. Sandborn WJ, Hanauer SB. PMID: 10338381.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    856. Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology. 1999 Apr; 116(4):1001-2; discussion 1002-3. Panaccione R, Sandborn WJ. PMID: 10092326.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    857. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci. 1999 Mar; 44(3):602-7. Angulo P, Bharucha AE, Jorgensen RA, DeSotel CK, Sandborn WJ, Larusso NF, Lindor KD. PMID: 10080157.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    858. Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Gastrointest Endosc. 1999 Feb; 49(2):153-7. Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ, Alexander GL, Balm RK, Gostout CJ. PMID: 9925691.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    859. Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Inflamm Bowel Dis. 1999 Feb; 5(1):33-9. Sandborn WJ, McLeod R, Jewell DP. PMID: 10028447.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    860. Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum. 1999 Jan; 42(1):117-20. Muñoz-Juarez M, Pemberton JH, Sandborn WJ, Tremaine WJ, Dozois RR. PMID: 10211531.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    861. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther. 1999 Jan; 65(1):29-39. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Fauq AH, Lipsky JJ. PMID: 9951428.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    862. Induction therapy with an intravenous loading dose of azathioprine for treatment of refractory, active rheumatoid arthritis. Arthritis Rheum. 1999 Jan; 42(1):186-7. Matteson EL, Orces CH, Duffy J, Lipsky JJ, Pike MG, Sandborn WJ. PMID: 9920030.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    863. Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology. 1998 Nov; 115(5):1295-6. Egan LJ, Sandborn WJ. PMID: 9797390.
      View in: PubMed   Mentions: 2     Fields:    Translation:Cells
    864. Association of primary sclerosing cholangitis and colorectal cancer in patients with ulcerative colitis: is it true and does it matter? Gastroenterology. 1998 Jul; 115(1):236-7. Sandborn WJ, Loftus EV, Ahlquist DA. PMID: 9649486.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    865. Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision. Aliment Pharmacol Ther. 1998 Jul; 12(7):679-84. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. PMID: 9701533.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    866. Nicotine carbomer enemas--pharmacokinetics of a revised formulation. Ital J Gastroenterol Hepatol. 1998 Jun; 30(3):260-5. Green JT, Rhodes J, Thomas GA, Evans BK, Feyerabend C, Russell MA, Sandborn WJ. PMID: 9759592.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    867. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998 Jun; 114(6):1161-8. Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. PMID: 9609752.
      View in: PubMed   Mentions: 178     Fields:    Translation:Humans
    868. Drug therapy of inflammatory bowel disease. Drugs Today (Barc). 1998 May; 34(5):431-46. Egan LJ, Sandborn WJ. PMID: 15010706.
      View in: PubMed   Mentions: 2     Fields:    
    869. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998 Apr; 93(4):504-14. Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT. PMID: 9576439.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    870. Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr. 1998 Apr; 26(4):386-92. Kaditis AG, Perrault J, Sandborn WJ, Landers CJ, Zinsmeister AR, Targan SR. PMID: 9552133.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    871. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology. 1998 Mar; 27(3):685-90. Loftus EV, Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RA, Zinsmeister AR, Graziadei IW, Wiesner RH. PMID: 9500695.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    872. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998 Mar; 93(3):442-8. Egan LJ, Sandborn WJ, Tremaine WJ. PMID: 9517654.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    873. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study. Cancer. 1998 Mar 01; 82(5):822-6. Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. PMID: 9486569.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    874. Inflammatory bowel disease and hereditary nonpolyposis colorectal cancer: is there a genetic link? Gastroenterology. 1998 Mar; 114(3):608-9. Sandborn WJ. PMID: 9496956.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    875. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1998; 225:92-9. Sandborn WJ. PMID: 9515759.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    876. Are short-chain fatty acid enemas effective for left-sided ulcerative colitis? Gastroenterology. 1998 Jan; 114(1):218-9. Sandborn WJ. PMID: 9428236.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    877. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 1997 Dec; 11(6):1041-6. Tremaine WJ, Sandborn WJ, Wolff BG, Carpenter HA, Zinsmeister AR, Metzger PP. PMID: 9663827.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    878. Nicotine enemas for active ulcerative colitis--a pilot study. Aliment Pharmacol Ther. 1997 Oct; 11(5):859-63. Green JT, Thomas GA, Rhodes J, Williams GT, Evans BK, Russell MA, Feyerabend C, Rhodes P, Sandborn WJ. PMID: 9354193.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    879. A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration. Aliment Pharmacol Ther. 1997 Oct; 11(5):865-74. Compton RF, Sandborn WJ, Lawson GM, Sheets AJ, Mays DC, Zins BJ, Tremaine WJ, Lipsky JJ, Mahoney DW, Zinsmeister AR, Offord KP, Hurt RD, Evans BK, Green J. PMID: 9354194.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    880. A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease. Gastroenterology. 1997 Sep; 113(3):1042-3. Sandborn WJ. PMID: 9288004.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    881. 6-MP metabolite levels: a potential guide to Crohn's disease therapy. Gastroenterology. 1997 Aug; 113(2):690-2. Sandborn WJ. PMID: 9247497.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    882. Lymphoma of the pouch after ileal pouch-anal anastomosis: report of a case. Dis Colon Rectum. 1997 Aug; 40(8):971-2. Nyam DC, Pemberton JH, Sandborn WJ, Savcenko M. PMID: 9269816.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    883. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther. 1997 Aug; 11(4):663-71. Sandborn WJ, Tremaine WJ, Leighton JA, Lawson GM, Zins BJ, Compton RF, Mays DC, Lipsky JJ, Batts KP, Offord KP, Hurt RD, Green J. PMID: 9305473.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    884. Dexpanthenol enemas in ulcerative colitis: a pilot study. Mayo Clin Proc. 1997 Jul; 72(7):616-20. Loftus EV, Tremaine WJ, Nelson RA, Shoemaker JD, Sandborn WJ, Phillips SF, Hasan Y. PMID: 9212762.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    885. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997 May; 92(5):876-9. Sandborn WJ. PMID: 9149205.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    886. Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. J Clin Pharmacol. 1997 May; 37(5):426-36. Zins BJ, Sandborn WJ, Mays DC, Lawson GM, McKinney JA, Tremaine WJ, Mahoney DW, Zinsmeister AR, Hurt RD, Offord KP, Lipsky JJ. PMID: 9156375.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    887. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997 Mar 01; 126(5):364-71. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD. PMID: 9054280.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    888. Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. Clin Pharmacol Ther. 1997 Mar; 61(3):340-8. Green JT, Thomas GA, Rhodes J, Evans BK, Russell MA, Feyerabend C, Fuller GS, Newcombe RG, Sandborn WJ. PMID: 9084459.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    889. Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc. 1997 Feb; 72(2):117-23. Levy AM, Gleich GJ, Sandborn WJ, Tremaine WJ, Steiner BL, Phillips SF. PMID: 9033543.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    890. Erythropoietin for inflammatory bowel disease anemia. Gastroenterology. 1997 Feb; 112(2):660-1. Sandborn W. PMID: 9024321.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    891. A new syndrome of Crohn's disease and pachydermoperiostosis in a family. Gastroenterology. 1997 Jan; 112(1):241-9. Compton RF, Sandborn WJ, Yang H, Lindor NM, Tremaine WJ, Davis MD, Khalil AA, Tountas NA, Tyan DB, Landers CJ, Taylor KD, Viggiano TR, Matteson EL, Schroeter AL, Plevy SE, Cominelli F, Targan SR, Rotter JI. PMID: 8978365.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    892. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. J Clin Pharmacol. 1997 Jan; 37(1):38-46. Zins BJ, Sandborn WJ, McKinney JA, Mays DC, van Os EC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ. PMID: 9048271.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    893. Does the surgical failure rate, increased incidence of pouchitis, and recent findings of dysplasia in pouches deter you from recommending an ileal pouch-anal anastomosis for ulcerative colitis? Inflamm Bowel Dis. 1997; 3(3):239-40. Sandborn WJ. PMID: 23282811.
      View in: PubMed   Mentions: 2     Fields:    
    894. Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis. 1997; 3(4):288-302. Loftus EV, Sandborn WJ, Lindor KD, Larusso NF. PMID: 23282876.
      View in: PubMed   Mentions: 18     Fields:    
    895. Long-term effects of antidepressants on balance, equilibrium, and postural reflexes. Psychiatry Res. 1996 Jul 31; 63(2-3):191-6. Li X, Hamdy R, Sandborn W, Chi D, Dyer A. PMID: 8878315.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    896. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut. 1996 Jul; 39(1):63-8. Van Os EC, Zins BJ, Sandborn WJ, Mays DC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ. PMID: 8881811; PMCID: PMC1383233.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    897. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996 May; 71(5):431-6. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. PMID: 8628021.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    898. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology. 1996 May; 110(5):1496-502. Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. PMID: 8613055.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    899. Simultaneous determination of azathioprine and 6-mercaptopurine by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Apr 26; 679(1-2):147-54. Van Os EC, McKinney JA, Zins BJ, Mays DC, Schriver ZH, Sandborn WJ, Lipsky JJ. PMID: 8998554.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    900. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996 Mar; 91(3):423-33. Sandborn WJ. PMID: 8633486.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    901. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996 Feb; 38(2):234-9. Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, Ilstrup D. PMID: 8801203; PMCID: PMC1383029.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    902. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology. 1996 Feb; 110(2):432-40. Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. PMID: 8566590.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    903. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. Am J Gastroenterol. 1996 Jan; 91(1):37-43. Sandborn WJ, Tremaine WJ, Lawson GM. PMID: 8561141.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    904. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc. 1996 Jan; 71(1):69-80. Egan LJ, Sandborn WJ. PMID: 8538238.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    905. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol. 1995 Dec; 90(12):2177-81. Zins BJ, Sandborn WJ, Penna CR, Landers CJ, Targan SR, Tremaine WJ, Wiesner RH, Dozois RR. PMID: 8540511.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    906. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology. 1995 Dec; 109(6):1808-17. Sandborn WJ, Van O EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. PMID: 7498645.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    907. Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology. 1995 Sep; 109(3):1001-3. Sandborn WJ. PMID: 7657085.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    908. Collagenous and lymphocytic colitis: subject review and therapeutic alternatives. Am J Gastroenterol. 1995 Sep; 90(9):1394-400. Zins BJ, Sandborn WJ, Tremaine WJ. PMID: 7661156.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    909. Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis. Dig Dis Sci. 1995 Jul; 40(7):1474-83. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Rossi SS, Hofmann AF, Gores GJ, Phillips SF. PMID: 7628271.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    910. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol. 1995 May; 90(5):740-7. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. PMID: 7733080.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    911. Drug therapy for inflammatory bowel disease. Contemp Intern Med. 1995 Apr; 7(4):21-34. Loftus EV, Sandborn WJ. PMID: 10150344.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    912. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology. 1995 Jan; 21(1):70-6. Sandborn WJ, Lawson GM, Cody TJ, Porayko MK, Hay JE, Gores GJ, Steers JL, Krom RA, Wiesner RH. PMID: 7528712.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    913. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994 Dec; 107(6):1856-60. Sandborn WJ. PMID: 7958702.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    914. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 1994 Jun; 106(6):1429-35. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR. PMID: 8194687.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    915. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994 May; 69(5):409-15. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. PMID: 8170189.
      View in: PubMed   Mentions: 177     Fields:    Translation:Humans
    916. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology. 1994 Apr; 19(4):925-32. Sandborn WJ, Hay JE, Porayko MK, Gores GJ, Steers JL, Krom RA, Wiesner RH. PMID: 8138267.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    917. High-volume postobstructive choleresis after transhepatic external biliary drainage resolves with conversion to internal drainage. J Clin Gastroenterol. 1993 Jul; 17(1):42-5. Sandborn WJ, Gross JB, Larson DE, Phillips JK, Lindor KD. PMID: 8409297.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    918. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol. 1993 May; 88(5):640-5. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM. PMID: 8480724.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    919. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut. 1993 Feb; 34(2):242-6. Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF. PMID: 8432481; PMCID: PMC1373978.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    920. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc. 1992 Oct; 67(10):981-90. Sandborn WJ, Tremaine WJ. PMID: 1434859.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    921. Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 1992 Aug; 15(2):125-9. Sandborn WJ, Goldman DH, Lawson GM, Perrault J. PMID: 1357126.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    922. Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology. 1992 Jun; 15(6):1086-91. Sandborn WJ, Lawson GM, Krom RA, Wiesner RH. PMID: 1592348.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    923. The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration. J Clin Pharmacol. 1991 Jan; 31(1):76-80. Sandborn WJ, Strong RM, Forland SC, Chase RE, Cutler RE. PMID: 2045532.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    924. Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. J Clin Pharmacol. 1990 Jun; 30(6):568-71. Sandborn WJ, Forland SC, Cutler RE, Strong RM. PMID: 2355107.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    William's Networks
    Concepts (1100)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (107)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California